<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03613649</url>
  </required_header>
  <id_info>
    <org_study_id>16-0110</org_study_id>
    <secondary_id>HHSN272201500005I</secondary_id>
    <nct_id>NCT03613649</nct_id>
  </id_info>
  <brief_title>Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-blinded, Four-period Crossover, Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Phase I Thorough QT/QTc (TQT) study will be performed in a single center, the Vince &amp;
      Associates Clinical Research, Inc., clinical trials unit (CTU), in 72 healthy male or female
      subjects, aged 18 to 45 years inclusive, to evaluate the effect of zoliflodacin on the
      corrected QT interval of the electrocardiogram (ECG) using Fridericia's Formula (QTcF) and
      other ECG parameters; the correlation of the drug concentrations (and pharmacokinetic (PK)
      profile) with time-matched, placebo-corrected, baseline-adjusted difference in QTcF interval
      (delta delta QTcF); and the PK and safety profiles of the new zoliflodacin formulation. Each
      subject will receive one dose of each of four treatments: zoliflodacin 2 g orally,
      zoliflodacin 4 g orally, placebo for zoliflodacin 4 g orally, and moxifloxacin 400 mg orally.
      The study will last approximately 12 weeks with a subject participation duration of up to 55
      days. The primary hypothesis to be tested is that following administration of zoliflodacin 2
      g and 4 g, the upper bound of the one-sided 95% confidence interval (CI) of treatment effect
      on delta delta QTcF is &gt; / = 10 msec for at least one of the ECG assessments, against the
      alternative hypothesis that all mean effects are &lt; 10 msec. The primary objective is to
      evaluate the effect of zoliflodacin on the corrected QT interval of the ECG using
      Fridericia's formula (QTcF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Phase I Thorough QT/QTc (TQT) study will be performed in a single center, the Vince &amp;
      Associates Clinical Research, Inc., clinical trials unit (CTU), according to a randomized,
      double-blinded (except for the use of moxifloxacin), placebo-controlled, four-period,
      four-treatment, crossover design balanced with respect to first-order carryover effect in 72
      healthy male or female subjects, aged 18 to 45 years inclusive, to evaluate the effect of
      zoliflodacin on the corrected QT interval of the electrocardiogram (ECG) using Fridericia's
      Formula (QTcF) and other ECG parameters; the correlation of the drug concentrations (and
      pharmacokinetic (PK) profile) with time-matched, placebo-corrected, baseline-adjusted
      difference in QTcF interval (delta delta QTcF); and the PK and safety profiles of the new
      zoliflodacin formulation. Each subject will receive one dose of each of four treatments:
      zoliflodacin 2 g orally, zoliflodacin 4 g orally, placebo for zoliflodacin 4 g orally, and
      moxifloxacin 400 mg orally. The study will last approximately 12 weeks with a subject
      participation duration of up to 55 days. The primary hypothesis to be tested is that
      following administration of zoliflodacin 2 g and 4 g, the upper bound of the one-sided 95%
      confidence interval (CI) of treatment effect on delta delta QTcF is &gt; / = 10 msec for at
      least one of the ECG assessments, against the alternative hypothesis that all mean effects
      are &lt; 10 msec. The primary objective is to evaluate the effect of zoliflodacin on the
      corrected QT interval of the ECG using Fridericia's formula (QTcF). The secondary objectives
      are: 1) to evaluate the effects of zoliflodacin on other ECG parameters (PR, QRS, and RR
      intervals, and heart rate (HR)); 2) to evaluate the sensitivity of QTcF measurement using
      moxifloxacin; 3) to evaluate the effect of zoliflodacin on T-wave morphology; 4) to evaluate
      the PK of 2 g and 4 g oral zoliflodacin under fasting state; 5) to evaluate the relationship
      between zoliflodacin PK and time-matched QTcF pharmacodynamics (PD); 6) to evaluate the
      safety and tolerability of 2 g and 4 g oral zoliflodacin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 25, 2018</start_date>
  <completion_date type="Actual">January 2, 2019</completion_date>
  <primary_completion_date type="Actual">January 2, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The One-sided 95% Confidence Interval (CI) for the Largest Time-matched, Placebo-corrected, Baseline-adjusted Mean QTcF Interval (Delta Delta QTcF) Following Administration of Zoliflodacin</measure>
    <time_frame>Baseline, 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose after 2 and 4 g zolifloadacin</time_frame>
    <description>Mean and 90% two-sided confidence intervals (t-intervals) of change from baseline QTcF intervals by time point and treatment. Note that the upper bound of the 90% two-sided confidence interval can also be interpreted as the upper bound of a 95% one-sided confidence interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-matched, Placebo-corrected, Baseline-adjusted Heart Rate (HR) Following Administration of Zoliflodacin</measure>
    <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
    <description>Mean and 90% two-sided confidence intervals (t-intervals) of change from baseline heart rate by time point and treatment. Note that the upper bound of the 90% two-sided confidence interval can also be interpreted as the upper bound of a 95% one-sided confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-matched, Placebo-corrected, Baseline-adjusted, the Time From the Onset of the P Wave to the Start of the QRS Complex (PR Interval) Following Administration of Zoliflodacin</measure>
    <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
    <description>Mean and 90% two-sided confidence intervals (t-intervals) of change from baseline PR intervals by time point and treatment. Note that the upper bound of the 90% two-sided confidence interval can also be interpreted as the upper bound of a 95% one-sided confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-matched, Placebo-corrected, Baseline-adjusted the Time Elapsed Between Two Successive R Waves of the QRS (RR Interval) Following Administration of Zoliflodacin</measure>
    <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
    <description>Mean and 90% two-sided confidence intervals (t-intervals) of change from baseline RR intervals by time point and treatment. Note that the upper bound of the 90% two-sided confidence interval can also be interpreted as the upper bound of a 95% one-sided confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-matched, Placebo-corrected, Baseline-adjusted QRS Duration Following Administration of Zoliflodacin</measure>
    <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
    <description>Mean and 90% two-sided confidence intervals (t-intervals) of change from baseline QRS durations by time point and treatment. Note that the upper bound of the 90% two-sided confidence interval can also be interpreted as the upper bound of a 95% one-sided confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The One-sided 95% Confidence Interval (CI) of the Time-matched, Placebo-corrected, Baseline-adjusted Mean QTcF Interval (Delta Delta QTcF) After a Single Dose of Moxifloxacin</measure>
    <time_frame>Baseline, 1 h, 2 h, 3 h, and 4 h post-dose</time_frame>
    <description>Mean and 90% two-sided confidence intervals (t-intervals) of change from baseline QTcF intervals by time point and treatment. Note that the upper bound of the 90% two-sided confidence interval can also be interpreted as the upper bound of a 95% one-sided confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Abnormal T-wave Morphology Following Administration of Zoliflodacin</measure>
    <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
    <description>Categorical T-wave morphology analysis was collected in three ECG replicates at each timepoint (Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose). Abnormalities present in any one or more of the baseline timepoint replicate ECGs recorded for a particular period was considered to be present at baseline for post-dose ECGs from that specific period. If a subject had an ECG morphological abnormality in more than one replicate ECG of a study timepoint, the subject was counted only once for that timepoint. Flat is defined as T amplitude &lt;1 mm (either positive or negative) including flat isoelectric line and Biphasic is defined as T-wave that contains a second component with an opposite phase that was at least 0.1 millivolts (mV) deep (both positive and negative/positive and polyphasic T-waves included).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Zoliflodacin</measure>
    <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
    <description>Cmax is defined as the maximum observed drug concentration observed in plasma over all PK sample concentrations computed from concentrations that were measured using a validated HPLC-MS/MS method. Pharmacokinetic (PK) parameters were computed using plasma concentrations from samples collected pre-dose and intervals post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Observed Concentration (Tmax) of Zoliflodacin</measure>
    <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
    <description>Tmax is defined as the time at which the maximum concentration (Cmax) occurs in plasma computed from concentrations that were measured using a validated HPLC-MS/MS method. PK parameters were computed using plasma concentrations from samples collected pre-dose and intervals post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time-curve From Time Zero to Infinity (AUC(0 - Infinity)) for Zoliflodacin</measure>
    <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
    <description>AUC(0 - infinity) was defined as the total area under the concentration-time curve from dosing (time 0) taken to the limit as the end time becomes arbitrarily large. AUC(0 - infinity) was calculated by adding AUC(0-last) to an extrapolated value equal to the last measured concentration greater than the lower limit of quantification of the bioanalytical assay divided by the terminal phase elimination rate constant (Ke) computed from concentrations that were measured using a validated HPLC-MS/MS method. PK parameters were computed using plasma concentrations from samples collected pre-dose and intervals post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time-curve From Time Zero to the Last Concentration Above the Lower Limit of Quantitation (AUC(0-last)) for Zoliflodacin</measure>
    <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
    <description>AUC(0-last) was defined as the area under the concentration-time curve from dosing (time 0) to the time of the last measured concentration computed from concentrations that were measured using a validated HPLC-MS/MS method. PK parameters were computed using plasma concentrations from samples collected pre-dose and intervals post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) of Zoliflodacin</measure>
    <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
    <description>Apparent volume of distribution during terminal phase (Vz/F) after non-intravenous administration was calculated as (CL/F)/ Ke computed from concentrations that were measured using a validated HPLC-MS/MS method. PK parameters were computed using plasma concentrations from samples collected pre-dose and intervals post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F) of Zoliflodacin</measure>
    <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
    <description>Apparent oral clearance (CL/F) computed as Dose/Area under the curve (AUC) from time zero to infinity (0-infinity) computed from concentrations that were measured using a validated high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method. PK parameters were computed using plasma concentrations from samples collected pre-dose and intervals post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Rate Constant (Ke) of Zoliflodacin</measure>
    <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
    <description>The terminal phase elimination rate constant (Ke) was defined as the first-order rate constant describing the rate of decrease of drug concentration in the terminal phase (defined as the terminal region of the PK curve where drug concentration follows first-order elimination kinetics) computed from concentrations that were measured using a validated HPLC-MS/MS method. PK parameters were computed using plasma concentrations from samples collected pre-dose and intervals post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-life (t1/2) of Zoliflodacin</measure>
    <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
    <description>The apparent terminal elimination half-life (t1/2) was defined as the time required for the drug concentration to decrease by a factor of one-half in the terminal phase computed from concentrations that were measured using a validated HPLC-MS/MS method. PK parameters were computed using plasma concentrations from samples collected pre-dose and intervals post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Plasma Concentrations of Zoliflodacin and Time-matched, Placebo-corrected, Baseline-adjusted Mean QTcF Interval (Delta Delta QTcF) Following Administration of Zoliflodacin</measure>
    <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
    <description>One-sided 95% confidence intervals of population mean QTcF time-matched, placebo-corrected, baseline-adjusted mean QTcF interval at plasma concentration corresponding to the observed geometric mean Cmax for 2 g and 4 g doses of zoliflodacin were computed using a linear mixed effect model with PK and concentration data collected at baseline and intervals post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Serious Adverse Events Following Administration of Zoliflodacin and Moxifloxacin</measure>
    <time_frame>From study product administration (Day 1) through prior to the next dose (Day 8 or Final visit).</time_frame>
    <description>Serious adverse events included any untoward medical occurrence that resulted in death; was life threatening; was a persistent/significant disability/incapacity; required inpatient hospitalization or prolongation or a congenital anomaly/birth defect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events Following Administration of Study Product</measure>
    <time_frame>From study product administration (Day 1) through prior to the next dose (Day 8 or Final visit).</time_frame>
    <description>Adverse events are defined as any untoward medical occurrence regardless of its causal relationship to the study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline for Blood Pressure - Systolic</measure>
    <time_frame>From study product administration (Day 1) through prior to the next dose (Day 8 or Final visit).</time_frame>
    <description>Change from baseline in systolic blood pressure was calculated by subtracting the baseline (pre-dose) measurement from the post-dose measurement. Post-dose measurements were taken 1 h, 2 h, 4 h and 24 h after dosing. Follow up is defined as the check in visit for the next dosing period or the final visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline for Blood Pressure - Diastolic</measure>
    <time_frame>From study product administration (Day 1) through prior to the next dose (Day 8 or Final visit).</time_frame>
    <description>Change from baseline in diastolic blood pressure was calculated by subtracting the baseline (pre-dose) measurement from the post-dose measurement. Post-dose measurements were taken 1 h, 2 h, 4 h and 24 h after dosing. Follow up is defined as the check in visit for the next dosing period or the final visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline for Pulse Rate</measure>
    <time_frame>From study product administration (Day 1) through prior to the next dose (Day 8 or Final visit).</time_frame>
    <description>Change from baseline in pulse rate was calculated by subtracting the baseline (pre-dose) measurement from the post-dose measurement. Post-dose measurements were taken 1 h, 2 h, 4 h and 24 h after dosing. Follow up is defined as the check in visit for the next dosing period or the final visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline for Respiratory Rate</measure>
    <time_frame>From study product administration (Day 1) through prior to the next dose (Day 8 or Final visit).</time_frame>
    <description>Change from baseline in respiratory rate was calculated by subtracting the baseline (pre-dose) measurement from the post-dose measurement. Post-dose measurements were taken 1 h, 2 h, 4 h and 24 h after dosing. Follow up is defined as the check in visit for the next dosing period or the final visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline for Temperature</measure>
    <time_frame>From study product administration (Day 1) through prior to the next dose (Day 8 or Final visit).</time_frame>
    <description>Change from baseline for temperature was calculated by subtracting the baseline (pre-dose) measurement from the post-dose measurement. Post-dose measurements were taken 1 h, 2 h, 4 h and 24 h after dosing. Follow up is defined as the check in visit for the next dosing period or the final visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline for White Blood Cells With Differentials</measure>
    <time_frame>Prior to dosing, 24 hour post dose through prior to the next dose (Day 8 or Final visit).</time_frame>
    <description>Change from baseline calculated by subtracting the Day -1 (baseline) hematology measurement from the 24 h post dose, and a follow up hematology measurement. Follow up is defined as either the check-in visit for the next period or the final visit. Hematology parameters included white blood cell count, and differential (absolute counts of neutrophils, lymphocytes, monocytes, eosinophils, and basophils).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline for Hemoglobin</measure>
    <time_frame>Prior to dosing, 24 hour post dose through prior to the next dose (Day 8 or Final visit).</time_frame>
    <description>Change from baseline for hemoglobin is calculated by subtracting the Day -1 (baseline) hematology measurement from the 24 h post dose, and a follow up hematology measurement. Follow up is defined as either the check-in visit for the next period or the final visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline for Hematocrit</measure>
    <time_frame>Prior to dosing, 24 hour post dose through prior to the next dose (Day 8 or Final visit).</time_frame>
    <description>Change from baseline for hematocrit is calculated by subtracting the Day -1 (baseline) hematology measurement from the 24 h post dose, and a follow up hematology measurement. Follow up is defined as either the check-in visit for the next period or the final visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline for Erythrocytes</measure>
    <time_frame>Prior to dosing, 24 hour post dose through prior to the next dose (Day 8 or Final visit).</time_frame>
    <description>Change from baseline for erythrocytes is calculated by subtracting the Day -1 (baseline) hematology measurement from the 24 h post dose, and a follow up hematology measurement. Follow up is defined as either the check-in visit for the next period or the final visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline for Platelets</measure>
    <time_frame>Prior to dosing, 24 hour post dose through prior to the next dose (Day 8 or Final visit).</time_frame>
    <description>Change from baseline for platelets is calculated by subtracting the Day -1 (baseline) hematology measurement from the 24 h post dose, and a follow up hematology measurement. Follow up is defined as either the check-in visit for the next period or the final visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline for Sodium, Potassium, Chloride and Bicarbonate</measure>
    <time_frame>Prior to dosing, 24 hour post dose through prior to the next dose (Day 8 or Final visit).</time_frame>
    <description>Change from baseline calculated by subtracting the Day -1 (baseline) chemistry measurement from the 24 h post dose, and a follow up chemistry measurement. Follow up is defined as either the check-in visit for the next period or the final visit. Chemistry parameters included sodium, potassium. chloride and bicarbonate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline for Magnesium, Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Total Bilirubin, Direct Bilirubin</measure>
    <time_frame>Prior to dosing, 24 hour post dose through prior to the next dose (Day 8 or Final visit).</time_frame>
    <description>Change from baseline calculated by subtracting the Day -1 (baseline) chemistry measurement from the 24 h post dose, and a follow up chemistry measurement. Follow up is defined as either the check-in visit for the next period or the final visit. Chemistry parameters included magnesium, glucose (fasting), BUN, creatinine, total bilirubin, direct bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline for Total Protein and Albumin</measure>
    <time_frame>Prior to dosing, 24 hour post dose through prior to the next dose (Day 8 or Final visit).</time_frame>
    <description>Change from baseline calculated by subtracting the Day -1 (baseline) chemistry measurement from the 24 h post dose, and a follow up chemistry measurement. Follow up is defined as either the check-in visit for the next period or the final visit. Chemistry parameters included total protein and albumin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline for Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase (AP)</measure>
    <time_frame>Prior to dosing, 24 hour post dose through prior to the next dose (Day 8 or Final visit).</time_frame>
    <description>Change from baseline calculated by subtracting the Day -1 (baseline) chemistry measurement from the 24 h post dose, and a follow up chemistry measurement. Follow up is defined as either the check-in visit for the next period or the final visit. Chemistry parameters included AST, ALT and AP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline for Glomerular Filtration Rate (GFR) - Estimated</measure>
    <time_frame>Prior to dosing, 24 hour post dose through prior to the next dose (Day 8 or Final visit).</time_frame>
    <description>Change from baseline calculated by subtracting the Day -1 (baseline) chemistry measurement from the 24 h post dose, and a follow up chemistry measurement. Follow up is defined as either the check-in visit for the next period or the final visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Urinalysis Adverse Events Following Administration of Study Product</measure>
    <time_frame>From study product administration (Day 1) through prior to the next dose (Day 8 or Final visit).</time_frame>
    <description>Urine for the clinical laboratory test was collected on Day -1, 24 hour post dose and the check in for the following dosing period. The results for glucose dipstick, protein dipstick and occult blood - dipstick were reported in categorical results. The possibilities were negative, trace, 1+, 2+, and 3+. If the dipsticks were 1+ or greater, microscopic evaluations were performed for erythrocytes, leukocytes and bacteria. For microscopic results to be deemed abnormal, the results must be reported 6 or greater per high power field.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in ECG Measures: PR Interval, QRS Duration, QT Interval, QTcF Interval and RR Interval</measure>
    <time_frame>Baseline, 1 h, 2 h, 4h, 24 h post-dose and follow up</time_frame>
    <description>Change from baseline in ECG is calculated by subtracting the baseline (pre-dose) measurement from the post-dose measurement. Post-dose measurements were taken 1 h, 2 h, 4 h, 24 h after dosing and prior to the next dose (follow up). The following ECG Parameters were analyzed: PR Interval (Interval From Onset of P-wave to the Onset of the QRS Complex), QRS Duration (Time From the Start of the Q-wave to the End of the S-wave), QT Interval (Interval From Onset of the Q-wave to the End of the T-wave), QTcF Interval (QT Interval Corrected by Fridericia's Formula) and RR Interval (Interval From the Peak of the R Wave of a QRS Complex to the Peak of the R Wave of the Next QRS Complex).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in ECG Measures: Ventricular Rate</measure>
    <time_frame>Baseline, 1 h, 2 h, 4h, 24 h post-dose and follow up</time_frame>
    <description>Change from baseline in ECG Ventricular Rate is calculated by subtracting the baseline (pre-dose) measurement from the post-dose measurement. Post-dose measurements were taken 1 h, 2 h, 4 h, 24 h after dosing and prior to the next dose (follow up).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Electrocardiogram Repolarisation Abnormality</condition>
  <condition>Gonococcal Infection</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period, n=72</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period, n=72</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for zoliflodacin administered orally on Day 1 of each dosing period, n=72</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 mg of moxifloxacin administered orally on Day 1 of each dosing period, n=72</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD0914</intervention_name>
    <description>Spiropyrimidinetrione antibacterial drug, which inhibits bacterial DNA synthesis by a novel mechanism. Powder will be reconstituted in 60 mL of tap water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin is taken, approximately 60 mL of tap water will be added to the cup and consumed by the subject to chase the initial dose.</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Broad-spectrum 8-methoxy fluoroquinolone with activity against both Gram-positive and Gram-negative bacteria, including anaerobes. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride will be administered orally with 120 mL of tap water.</description>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Composed of 4 g of the same excipients found in zoliflodacin. Powder will be reconstituted in 60 mL of tap water and dosed orally after an overnight fast. After the cup containing 60 mL of placebo is taken, approximately 60 mL of tap water will be added to the cup and consumed by the subject to chase the initial dose.</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All must be answered YES for the subject to be eligible for study participation:

          1. Informed consent form (ICF) understood and signed before initiating any study
             procedures

          2. Healthy male or female, as assessed by authorized site clinician (listed on FDA Form
             1572)

          3. Willingness to comply with and be available for all protocol procedures, including
             inpatient confinement for 3 days in each dosing period and follow-up for the duration
             of the trial

          4. Aged 18 to 45 years inclusive on the day of first dosing

          5. Body Mass Index (BMI) &gt; / = 18.5 and &lt; / = to 30 kg per m^2 and weight &gt; / = 50 kg
             (110 lbs.) and &lt; / = 100 kg (220 lbs.)

          6. In all female subjects, whether of childbearing potential or post-menopausal by
             medical history (MH), a negative serum pregnancy test at Screening Visit and on Day -1
             of each dosing period

             -Note: A woman is considered of childbearing potential unless post-menopausal (&gt; / = 1
             year without menses without other known or suspected cause and with a FSH level in the
             menopausal range), or surgically sterilized (hysterectomy, salpingectomy,
             oophorectomy, or tubal ligation/occlusion).

          7. If female, not pregnant, not breast feeding, and not planning to become pregnant
             during the trial and for 30 days after Final Visit

          8. Females of childbearing potential and males agree to use acceptable contraception for
             the duration of the trial and for 30 days (females) or 90 days (males) after Final
             Visit

             -Note: A highly effective method of birth control is defined as one with a low failure
             rate (i.e., less than 1 percent per year) according to CDC criteria. These include
             progestin implants, intrauterine devices (IUDs), surgical (hysterectomy,
             salpingectomy, oophorectomy, or tubal ligation/occlusion; vasectomy), or abstinence.
             Use of methods with higher failure rate (such as progestin injectables, combined oral
             hormonal contraceptives, condoms, and diaphragms) will not be acceptable when used
             alone, but they could be considered if used in combination with another method (e.g.,
             a female using combined oral contraceptives if her male partner is sterile, or if she
             and her non-sterile male partner use a double-barrier method), after consultation with
             the DMID Medical Officer.

          9. Male subjects agree to refrain from sperm donation for the duration of the trial and
             for 90 days after Final Visit

         10. Laboratory tests are in the normal reference range with acceptable exceptions

         11. Vital signs (VS) are within the acceptable range

         12. Has adequate venous access for blood collection

         13. Urine drug screen is negative for tested substances

         14. Urine alcohol test is negative

         15. Willing to abstain from alcohol consumption for 2 days before Day -1 of Period 1 and
             for the duration of the trial

        Exclusion Criteria:

        All must be answered NO for the subject to be eligible for study participation:

        1. History of acute or chronic cardiovascular disease or surgery

          -  Note: Conditions include: congestive heart failure; coronary artery disease
             (myocardial infarction, unstable angina); cerebrovascular disease (cerebrovascular
             accident or stroke or transient ischemic attack (TIA); chronic hypertension; or
             coronary revascularization surgery (coronary artery bypass grafting or percutaneous
             transluminal coronary angioplasty) 2. History of cardiac arrhythmia or syncope related
             to cardiac arrhythmia or unexplained, or use of a cardiac pacemaker

          -  Note: Conditions include: atrial fibrillation, atrial flutter, or non-sustained or
             sustained ventricular tachycardia; use of a cardiac pacemaker; personal or family
             history of LQTS; or family history of sudden death 3. History of any other chronic
             medical or surgical condition that would interfere with the accurate assessment of the
             trial's objectives or increase the subject's risk profile

          -  Note: Chronic medical conditions include: diabetes mellitus; asthma requiring use of
             medication in the year before screening; autoimmune disorder such as lupus
             erythematosus, Wegener's, rheumatoid arthritis, thyroid disease; malignancy except
             low-grade (squamous and basal cell) skin cancer thought to be cured; chronic renal,
             hepatic, pulmonary, or endocrine disease, myopathy, or neuropathy; gastrointestinal
             surgery including weight loss surgery or biliary surgery 4. Major surgical
             interventions are not permitted within 4 weeks of first dosing and during the trial.
             Minor surgical interventions are not allowed within 2 weeks of first dosing and during
             the trial 5. History of hypersensitivity or severe allergic reaction of any type to
             medications, bee stings, food, or environmental factors

          -  Note: Severe allergic reaction is defined as any of the following: anaphylaxis,
             urticaria, or angioedema 6. Active allergic symptoms to seasonal and animal allergens
             that are moderate to severe, affect daily activity, and require continuous treatment
             7. A marked baseline prolongation of ECG intervals, or HR less than 45 bpm or greater
             than 100 bpm on ECG measurements

          -  Note: The following are considered prolonged ECG intervals: QTc/QTcF &gt; 449 msec in
             males and females; PR &gt; 209 msec; and QRS &gt; 110 msec 8. Clinically significant
             abnormal ECG results

          -  Note: Clinically significant abnormal ECG results include: complete left or right
             bundle branch block; other ventricular conduction block; 2nd degree or 3rd degree
             atrioventricular (AV) block; sustained atrial or ventricular arrhythmia; two premature
             ventricular contractions in a row; pattern of ST elevation felt consistent with
             cardiac ischemia; evidence of a previous myocardial infarction (MI), left ventricular
             hypertrophy (LVH), or more than minor non-specific ST-T wave changes; any
             characteristics that would make QT assessment unreliable, including flat T waves; or
             any condition deemed clinically significant by a study investigator 9. Abnormal renal
             function

          -  Note: Normal renal function is defined as normal creatinine and normal estimated
             glomerular filtration rate (eGFR) [i.e., &gt; 80.0 mL/min] values according to
             Cockroft-Gault 10. Positive serology results for HIV, HBsAg, or HCV 11. Febrile
             illness with temperature &gt; / = 38.0 degrees Celsius for &lt; 7 days before dosing in each
             treatment period 12. Donated whole blood or blood products within 60 days before first
             dosing, or plans to donate or receive before Final Visit (Day 8 + / - 2 after last
             dose in dosing period 4)

          -  Note: Blood products include RBCs, white blood cells (WBCs), platelets, and plasma 13.
             Known allergic reactions to fluoroquinolones or to components present in the
             formulation or processing of zoliflodacin and moxifloxacin 14. Treatment with another
             investigational product within 30 days of first dosing or 5 half-lives or twice the
             duration of the biological effect of the study drug (whichever is longer)

          -  Note: Investigational products include a drug, vaccine, biologic, device, or blood
             product 15. Active drug or alcohol binge consumption, abuse, or dependence within 12
             months before Screening Visit that, in the opinion of the investigator, would
             interfere with adherence to study requirements 16. Use of any prescription medication
             within 30 days before first dosing or planned use during the trial except as noted
             below and approved by the designated study clinician

          -  Note 1: Prohibited medications include moderate or strong CYP3A4 inducers and other
             drugs with known risk for QT prolongation and TdP; antibiotics; injectable or oral
             antidiabetic drugs; anti-lipid drugs; immunosuppressive agents; immune modulators;
             oral corticosteroids; anti-neoplastic agents; any vaccine (licensed or
             investigational) except licensed influenza vaccine during the flu season, which is
             allowed up to 7 days before first dosing or 7 days after last dosing

          -  Note 2: Allowed medications include: oral contraceptives; H1 antihistamines; all
             medications approved for control of intraocular pressure including topical ophthalmic
             non-selective beta-blockers, such as betaxolol, carteolol, levobunolol, metipranolol,
             and timolol; topical/ intranasal corticosteroids; nonsteroidal anti-inflammatory drugs
             (NSAIDS); licensed influenza vaccine during the flu season, 7 days before first dosing
             or 7 days after last dosing 17. Use of non-prescription medications, vitamins, herbs,
             or nutritional supplements within 15 days before first dosing or planned use during
             the trial unless approved by the study clinician

          -  Note 1: Intake of nutritional supplements, juice, and herbal preparations or other
             foods or beverages that may affect the various drug-metabolizing enzymes and
             transporters (e.g., grapefruit, grapefruit juice, grapefruit-containing beverages,
             apple or orange juice, vegetables from the mustard green family [e.g., kale, broccoli,
             watercress, collard greens, kohlrabi, Brussels sprouts, mustard], and charbroiled
             meats) within 7 days before dosing

          -  Note 2: Exceptions: St. John's wart is not allowed within 30 days of dosing; vitamins
             and over-the-counter (OTC) medications taken for a brief period (less than 48 h) for
             the treatment of common symptoms (such as headache, indigestion, muscle pain) may be
             allowed as approved by the designated study clinician 18. Intake of caffeinated
             beverages or food within 72 h before first dosing or a history of high caffeine
             consumption (e.g., in the last 4 months drinking &gt; 5 cups of coffee/day) 19. Smoking
             or use of tobacco or nicotine-containing products within 30 days before first dosing
             20. Engagement in strenuous exercise within 15 days before first dosing (e.g.,
             marathon running, long-distance cycling, weight lifting) and during the trial 21. Any
             specific behavioral or clinical condition that, in the judgment of the investigator,
             precludes participation because it could affect compliance with study procedures or
             subject safety 22. Plans to enroll or is already enrolled in another clinical trial
             that could interfere with safety assessment of the study drug at any time during the
             trial

          -  Note: Includes trials that have a study intervention such as a drug, biologic, or
             device 23. Is a CTU employee or staff member who is paid entirely or partially by the
             Office of Clinical Research Resources (OCRR)/NIAID contract for the DMID-funded trial

          -  Note: CTU employees or staff include the PIs, sub-investigators, or staff who are
             supervised by the PI or sub-investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vince and Associates Clinical Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 7, 2019</verification_date>
  <study_first_submitted>July 26, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <results_first_submitted>December 24, 2019</results_first_submitted>
  <results_first_submitted_qc>March 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 27, 2020</results_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AZD0914</keyword>
  <keyword>Cardiac</keyword>
  <keyword>ETX0914</keyword>
  <keyword>Healthy</keyword>
  <keyword>Moxifloxacin</keyword>
  <keyword>Repolarization</keyword>
  <keyword>Study</keyword>
  <keyword>TQT</keyword>
  <keyword>Volunteers</keyword>
  <keyword>Zoliflodacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gonorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT03613649/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT03613649/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was performed at a commercial phase 1 unit. Recruitment opened on September 4, 2018 and all 72 participants were consented and screened for meeting eligibility criteria prior to enrollment and dosing. Enrollment was completed on December 04, 2018.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>2g Zoliflodacin, 4g Zoliflodacin, Placebo, 400mg Moxifloxacin</title>
          <description>Treatment ABCD: 2 g of zoliflodacin administered orally on Day 1, then an 8 day wash out 4 g of zoliflodacin was taken, then another 8 day wash out placebo was taken and then after the final 8 day wash out 400mg of moxifloxacin was taken.
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
        </group>
        <group group_id="P2">
          <title>2g Zoliflodacin, Placebo, 400mg Moxifloxacin, 4g Zoliflodacin</title>
          <description>Treatment ACDB: 2 g of zoliflodacin administered orally on Day 1, then an 8 day wash out placebo was taken, then another 8 day wash out, 400 mg moxifloxacin was taken and then after the final 8 day wash out 4 g of zoliflodacin was taken.
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
        </group>
        <group group_id="P3">
          <title>2g Zoliflodacin, 400mg Moxifloxacin, 4g Zoliflodacin, Placebo</title>
          <description>Treatment ADBC: 2 g of zoliflodacin administered orally on Day 1, then an 8 day wash out 400mg of moxifloxacin was taken, then another 8 day wash out 4g of zoliflodacin was taken and then after the final 8 day wash out placebo was taken.
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
        </group>
        <group group_id="P4">
          <title>4g Zoliflodacin, 2g Zoliflodacin, 400mg Moxifloxacin, Placebo</title>
          <description>Treatment BADC: 4 g of zoliflodacin administered orally on Day 1, then an 8 day wash out 2 g of zoliflodacin was taken, then another 8 day wash out 400mg of moxifloxacin was taken and then after the final 8 day wash out placebo was taken.
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
        </group>
        <group group_id="P5">
          <title>4g Zoliflodacin, 400mg Moxifloxacin, Placebo, 2g Zoliflodacin,</title>
          <description>Treatment BDCA: 4 g of zoliflodacin administered orally on Day 1, then an 8 day wash out 400mg of moxifloxacin was taken, then another 8 day wash out placebo was taken and then after the final 8 day wash out 2 g of zoliflodacin was taken.
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
        </group>
        <group group_id="P6">
          <title>4g Zoliflodacin, Placebo, 2g Zoliflodacin, 400mg Moxifloxacin</title>
          <description>Treatment BCAD: 4 g of zoliflodacin administered orally on Day 1, then an 8 day wash out placebo was taken, then another 8 day wash out 2 g of zoliflodacin was taken and then after the final 8 day wash out 400mg of moxifloxacin was taken.
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
        </group>
        <group group_id="P7">
          <title>Placebo, 400mg Moxifloxacin, 2g Zoliflodacin, 4g Zoliflodacin,</title>
          <description>Treatment CDAB: Placebo administered orally on Day 1, then an 8 day wash out 400mg of moxifloxacin was taken, then another 8 day wash out 2 g of zoliflodacin was taken and then after the final 8 day wash out 4 g of zoliflodacin was taken.
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
        </group>
        <group group_id="P8">
          <title>Placebo, 2g Zoliflodacin, 4g Zoliflodacin, 400mg Moxifloxacin</title>
          <description>Treatment CABD: Placebo administered orally on Day 1, then an 8 day wash out 2 g of zoliflodacin was taken, then another 8 day wash out 4 g of zoliflodacin was taken and then after the final 8 day wash out 400mg of moxifloxacin was taken.
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
        </group>
        <group group_id="P9">
          <title>Placebo, 4g Zoliflodacin, 400mg Moxifloxacin, 2g Zoliflodacin</title>
          <description>Treatment CBDA: Placebo administered orally on Day 1, then an 8 day wash out 4 g of zoliflodacin was taken, then another 8 day wash out 400mg of moxifloxacin was taken and then after the final 8 day wash out 2 g of zoliflodacin was taken.
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
        </group>
        <group group_id="P10">
          <title>400mg Moxifloxacin, Placebo, 4g Zoliflodacin, 2g Zoliflodacin</title>
          <description>Treatment DCBA: 400mg of moxifloxacin was administered orally on Day 1, then an 8 day wash out placebo was taken, then another 8 day wash out 4 g of zoliflodacin was taken and then after the final 8 day wash out 2 g of zoliflodacin was taken.
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
        </group>
        <group group_id="P11">
          <title>400mg Moxifloxacin, 4g Zoliflodacin, 2g Zoliflodacin, Placebo</title>
          <description>Treatment DBAC: 400mg of moxifloxacin was administered orally on Day 1, then an 8 day wash out 4 g of zoliflodacin was taken, then another 8 day wash out 2 g of zoliflodacin was taken and then after the final 8 day wash out placebo was taken.
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
        </group>
        <group group_id="P12">
          <title>400mg Moxifloxacin, 2g Zoliflodacin, Placebo, 4g Zoliflodacin</title>
          <description>Treatment DACB: 400mg of moxifloxacin was administered orally on Day 1, then an 8 day wash out 2 g of zoliflodacin was taken, then another 8 day wash out placebo was taken and then after the final 8 day wash out 4 g of zoliflodacin was taken.
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Third Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Fourth Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2g Zoliflodacin, 4g Zoliflodacin, Placebo, 400mg Moxifloxacin</title>
          <description>Treatment ABCD: 2 g of zoliflodacin administered orally on Day 1, then an 8 day wash out 4 g of zoliflodacin was taken, then another 8 day wash out placebo was taken and then after the final 8 day wash out 400mg of moxifloxacin was taken.
AZD0914: Spiropyrimidinetrione antibacterial drug, Powder was reconstituted in 60 mL of water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin was taken, approximately 60 mL of water was added and consumed by the subject to chase the initial dose.
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
        </group>
        <group group_id="B2">
          <title>2g Zoliflodacin, Placebo, 400mg Moxifloxacin, 4g Zoliflodacin</title>
          <description>Treatment ACDB: 2 g of zoliflodacin administered orally on Day 1, then an 8 day wash out placebo was taken, then another 8 day wash out, 400 mg moxifloxacin was taken and then after the final 8 day wash out 4 g of zoliflodacin was taken.
AZD0914: Spiropyrimidinetrione antibacterial drug, Powder was reconstituted in 60 mL of water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin was taken, approximately 60 mL of water was added and consumed by the subject to chase the initial dose.
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water..</description>
        </group>
        <group group_id="B3">
          <title>2g Zoliflodacin, 400mg Moxifloxacin, 4g Zoliflodacin, Placebo</title>
          <description>Treatment ADBC: 2 g of zoliflodacin administered orally on Day 1, then an 8 day wash out 400mg of moxifloxacin was taken, then another 8 day wash out 4g of zoliflodacin was taken and then after the final 8 day wash out placebo was taken.
AZD0914: Spiropyrimidinetrione antibacterial drug, Powder was reconstituted in 60 mL of water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin was taken, approximately 60 mL of water was added and consumed by the subject to chase the initial dose.
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
        </group>
        <group group_id="B4">
          <title>4g Zoliflodacin, 2g Zoliflodacin, 400mg Moxifloxacin, Placebo</title>
          <description>Treatment BADC: 4 g of zoliflodacin administered orally on Day 1, then an 8 day wash out2 g of zoliflodacin was taken, then another 8 day wash out 400mg of moxifloxacin was taken and then after the final 8 day wash out placebo was taken.
AZD0914: Spiropyrimidinetrione antibacterial drug, Powder was reconstituted in 60 mL of water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin was taken, approximately 60 mL of water was added and consumed by the subject to chase the initial dose.
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
        </group>
        <group group_id="B5">
          <title>4g Zoliflodacin, 400mg Moxifloxacin, Placebo, 2g Zoliflodacin,</title>
          <description>Treatment BDCA: 4 g of zoliflodacin administered orally on Day 1, then an 8 day wash out 400mg of moxifloxacin was taken, then another 8 day wash out placebo was taken and then after the final 8 day wash out 2 g of zoliflodacin was taken.
AZD0914: Spiropyrimidinetrione antibacterial drug, Powder was reconstituted in 60 mL of water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin was taken, approximately 60 mL of water was added and consumed by the subject to chase the initial dose.
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
        </group>
        <group group_id="B6">
          <title>4g Zoliflodacin, Placebo, 2g Zoliflodacin, 400mg Moxifloxacin</title>
          <description>Treatment BCAD: 4 g of zoliflodacin administered orally on Day 1, then an 8 day wash out placebo was taken, then another 8 day wash out 2 g of zoliflodacin was taken and then after the final 8 day wash out 400mg of moxifloxacin was taken.
AZD0914: Spiropyrimidinetrione antibacterial drug, Powder was reconstituted in 60 mL of water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin was taken, approximately 60 mL of water was added and consumed by the subject to chase the initial dose.
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
        </group>
        <group group_id="B7">
          <title>Placebo, 400mg Moxifloxacin, 2g Zoliflodacin, 4g Zoliflodacin,</title>
          <description>Treatment CDAB: Placebo administered orally on Day 1, then an 8 day wash out 400mg of moxifloxacin was taken, then another 8 day wash out 2 g of zoliflodacin was taken and then after the final 8 day wash out4 g of zoliflodacin was taken.
AZD0914: Spiropyrimidinetrione antibacterial drug, Powder was reconstituted in 60 mL of water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin was taken, approximately 60 mL of water was added and consumed by the subject to chase the initial dose.
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
        </group>
        <group group_id="B8">
          <title>Placebo, 2g Zoliflodacin, 4g Zoliflodacin, 400mg Moxifloxacin</title>
          <description>Treatment CABD: Placebo administered orally on Day 1, then an 8 day wash out 2 g of zoliflodacin was taken, then another 8 day wash out 4 g of zoliflodacin was taken and then after the final 8 day wash out 400mg of moxifloxacin was taken.
AZD0914: Spiropyrimidinetrione antibacterial drug, Powder was reconstituted in 60 mL of water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin was taken, approximately 60 mL of water was added and consumed by the subject to chase the initial dose.
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
        </group>
        <group group_id="B9">
          <title>Placebo, 4g Zoliflodacin, 400mg Moxifloxacin, 2g Zoliflodacin</title>
          <description>Treatment CBDA: Placebo administered orally on Day 1, then an 8 day wash out 4 g of zoliflodacin was taken, then another 8 day wash out 400mg of moxifloxacin was taken and then after the final 8 day wash out 2 g of zoliflodacin was taken.
AZD0914: Spiropyrimidinetrione antibacterial drug, Powder was reconstituted in 60 mL of water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin was taken, approximately 60 mL of water was added and consumed by the subject to chase the initial dose.
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
        </group>
        <group group_id="B10">
          <title>400mg Moxifloxacin, Placebo, 4g Zoliflodacin, 2g Zoliflodacin</title>
          <description>Treatment DCBA: 400mg of moxifloxacin was administered orally on Day 1, then an 8 day wash out placebo was taken, then another 8 day wash out 4 g of zoliflodacin was taken and then after the final 8 day wash out 2 g of zoliflodacin was taken.
AZD0914: Spiropyrimidinetrione antibacterial drug, Powder was reconstituted in 60 mL of water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin was taken, approximately 60 mL of water was added and consumed by the subject to chase the initial dose.
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
        </group>
        <group group_id="B11">
          <title>400mg Moxifloxacin, 4g Zoliflodacin, 2g Zoliflodacin, Placebo</title>
          <description>Treatment DBAC: 400mg of moxifloxacin was administered orally on Day 1, then an 8 day wash out 4 g of zoliflodacin was taken, then another 8 day wash out 2 g of zoliflodacin was taken and then after the final 8 day wash out placebo was taken.
AZD0914: Spiropyrimidinetrione antibacterial drug, Powder was reconstituted in 60 mL of water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin was taken, approximately 60 mL of water was added and consumed by the subject to chase the initial dose.
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
        </group>
        <group group_id="B12">
          <title>400mg Moxifloxacin, 2g Zoliflodacin, Placebo, 4g Zoliflodacin</title>
          <description>Treatment DACB: 400mg of moxifloxacin was administered orally on Day 1, then an 8 day wash out 2 g of zoliflodacin was taken, then another 8 day wash out placebo was taken and then after the final 8 day wash out 4 g of zoliflodacin was taken.
AZD0914: Spiropyrimidinetrione antibacterial drug, Powder was reconstituted in 60 mL of water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin was taken, approximately 60 mL of water was added and consumed by the subject to chase the initial dose.
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
        </group>
        <group group_id="B13">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="6"/>
            <count group_id="B11" value="6"/>
            <count group_id="B12" value="6"/>
            <count group_id="B13" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.8" spread="4.4"/>
                    <measurement group_id="B2" value="29.7" spread="4.7"/>
                    <measurement group_id="B3" value="32.5" spread="4.7"/>
                    <measurement group_id="B4" value="36.3" spread="7.4"/>
                    <measurement group_id="B5" value="30.0" spread="7.3"/>
                    <measurement group_id="B6" value="32.5" spread="8.1"/>
                    <measurement group_id="B7" value="31.7" spread="9.4"/>
                    <measurement group_id="B8" value="34.2" spread="5.5"/>
                    <measurement group_id="B9" value="28.7" spread="4.5"/>
                    <measurement group_id="B10" value="30.8" spread="8.9"/>
                    <measurement group_id="B11" value="31.2" spread="7.1"/>
                    <measurement group_id="B12" value="29.0" spread="6.8"/>
                    <measurement group_id="B13" value="31.7" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.60" spread="3.20"/>
                    <measurement group_id="B2" value="23.98" spread="2.78"/>
                    <measurement group_id="B3" value="24.48" spread="2.76"/>
                    <measurement group_id="B4" value="24.57" spread="3.28"/>
                    <measurement group_id="B5" value="26.10" spread="2.50"/>
                    <measurement group_id="B6" value="25.07" spread="3.48"/>
                    <measurement group_id="B7" value="26.80" spread="1.58"/>
                    <measurement group_id="B8" value="25.67" spread="2.43"/>
                    <measurement group_id="B9" value="23.43" spread="3.72"/>
                    <measurement group_id="B10" value="26.30" spread="1.68"/>
                    <measurement group_id="B11" value="25.35" spread="3.71"/>
                    <measurement group_id="B12" value="25.03" spread="2.83"/>
                    <measurement group_id="B13" value="25.03" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kiliograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.38" spread="11.89"/>
                    <measurement group_id="B2" value="68.05" spread="11.16"/>
                    <measurement group_id="B3" value="72.65" spread="14.07"/>
                    <measurement group_id="B4" value="70.05" spread="14.31"/>
                    <measurement group_id="B5" value="80.28" spread="13.93"/>
                    <measurement group_id="B6" value="73.63" spread="14.97"/>
                    <measurement group_id="B7" value="80.63" spread="7.84"/>
                    <measurement group_id="B8" value="75.40" spread="8.74"/>
                    <measurement group_id="B9" value="75.57" spread="17.40"/>
                    <measurement group_id="B10" value="78.88" spread="10.18"/>
                    <measurement group_id="B11" value="77.02" spread="10.28"/>
                    <measurement group_id="B12" value="70.85" spread="14.62"/>
                    <measurement group_id="B13" value="74.53" spread="12.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The One-sided 95% Confidence Interval (CI) for the Largest Time-matched, Placebo-corrected, Baseline-adjusted Mean QTcF Interval (Delta Delta QTcF) Following Administration of Zoliflodacin</title>
        <description>Mean and 90% two-sided confidence intervals (t-intervals) of change from baseline QTcF intervals by time point and treatment. Note that the upper bound of the 90% two-sided confidence interval can also be interpreted as the upper bound of a 95% one-sided confidence interval.</description>
        <time_frame>Baseline, 0.5 hour (h), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose after 2 and 4 g zolifloadacin</time_frame>
        <population>The analysis population sample size is equal to the number of subjects in the Holter ECG Analysis Population who received a dose of zoliflodacin or a dose of placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of dosing period.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of dosing period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo was administered orally on Day 1 of dosing period.</description>
          </group>
        </group_list>
        <measure>
          <title>The One-sided 95% Confidence Interval (CI) for the Largest Time-matched, Placebo-corrected, Baseline-adjusted Mean QTcF Interval (Delta Delta QTcF) Following Administration of Zoliflodacin</title>
          <description>Mean and 90% two-sided confidence intervals (t-intervals) of change from baseline QTcF intervals by time point and treatment. Note that the upper bound of the 90% two-sided confidence interval can also be interpreted as the upper bound of a 95% one-sided confidence interval.</description>
          <population>The analysis population sample size is equal to the number of subjects in the Holter ECG Analysis Population who received a dose of zoliflodacin or a dose of placebo.</population>
          <units>milliseconds (msec)</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" lower_limit="-4.12" upper_limit="-2.21"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-2.08" upper_limit="0.17"/>
                    <measurement group_id="O3" value="-2.1" lower_limit="-2.89" upper_limit="-1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" lower_limit="-2.81" upper_limit="-1.04"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-1.03" upper_limit="1.18"/>
                    <measurement group_id="O3" value="-2.3" lower_limit="-3.34" upper_limit="-1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" lower_limit="-3.43" upper_limit="-1.25"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-1.25" upper_limit="1.47"/>
                    <measurement group_id="O3" value="-2.2" lower_limit="-3.30" upper_limit="-1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" lower_limit="-2.79" upper_limit="-0.41"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-1.54" upper_limit="1.69"/>
                    <measurement group_id="O3" value="-2.6" lower_limit="-3.78" upper_limit="-1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" lower_limit="-3.83" upper_limit="-0.89"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-1.14" upper_limit="1.35"/>
                    <measurement group_id="O3" value="-3.3" lower_limit="-4.36" upper_limit="-2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-3.50" upper_limit="-0.50"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-2.37" upper_limit="1.07"/>
                    <measurement group_id="O3" value="-2.3" lower_limit="-4.55" upper_limit="-0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" lower_limit="-7.25" upper_limit="-3.88"/>
                    <measurement group_id="O2" value="-4.7" lower_limit="-6.08" upper_limit="-3.26"/>
                    <measurement group_id="O3" value="-4.4" lower_limit="-6.23" upper_limit="-2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" lower_limit="-4.28" upper_limit="-1.33"/>
                    <measurement group_id="O2" value="-0.4" lower_limit="-2.07" upper_limit="1.24"/>
                    <measurement group_id="O3" value="-2.2" lower_limit="-4.11" upper_limit="-0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" lower_limit="-4.17" upper_limit="-1.53"/>
                    <measurement group_id="O2" value="-0.3" lower_limit="-1.49" upper_limit="0.93"/>
                    <measurement group_id="O3" value="-2.2" lower_limit="-3.69" upper_limit="-0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Zoliflodacin administered at a 2 g dose causes a prolongation of the QTcF interval 0.5 h post-dose that exceeds the criteria in the ICH Guidance E14 (5 ms).
Power Calculation:
Enrollment of 72 subjects would provide at least 84% power to conclude a negative effect, given that up to 16 subjects may withdraw early prior to beginning to replace subjects (at least 56 subjects evaluable), and assuming a standard deviation of QTcF of 7 msec and an underlying effect of 5 msec.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Per ICH E14, an increase in the QTcF interval of 5 ms, as evidenced by the upper bound of a 95% one-sided confidence interval above 0.10, is the threshold for regulatory concern. Statistically, the test of prolongation is equivalent to a non-inferiority test versus placebo by crossover design, with an non-inferiority margin of 10 ms.</non_inferiority_desc>
            <param_type>Least-Squares Mean Double Delta Value</param_type>
            <param_value>-0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>0.635</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Zoliflodacin administered at a 2 g dose causes a prolongation of the QTcF interval 1 h post-dose that exceeds the criteria in the ICH Guidance E14 (5 ms).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Per ICH E14, an increase in the QTcF interval of 5 ms, as evidenced by the upper bound of a 95% one-sided confidence interval above 0.10, is the threshold for regulatory concern.</non_inferiority_desc>
            <param_type>Least-Squares Mean Double Delta Value</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>2.200</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Zoliflodacin administered at a 2 g dose causes a prolongation of the QTcF interval 2 h post-dose that exceeds the criteria in the ICH Guidance E14 (5 ms).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Per ICH E14, an increase in the QTcF interval of 5 ms, as evidenced by the upper bound of a 95% one-sided confidence interval above 0.10, is the threshold for regulatory concern.</non_inferiority_desc>
            <param_type>Least-Squares Mean Double Delta Value</param_type>
            <param_value>0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>1.795</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Zoliflodacin administered at a 2 g dose causes a prolongation of the QTcF interval 3 h post-dose that exceeds the criteria in the ICH Guidance E14 (5 ms).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Per ICH E14, an increase in the QTcF interval of 5 ms, as evidenced by the upper bound of a 95% one-sided confidence interval above 0.10, is the threshold for regulatory concern.</non_inferiority_desc>
            <param_type>Least-Squares Mean Double Delta Value</param_type>
            <param_value>1.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>3.044</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Zoliflodacin administered at a 2 g dose causes a prolongation of the QTcF interval 4 h post-dose that exceeds the criteria in the ICH Guidance E14 (5 ms).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Per ICH E14, an increase in the QTcF interval of 5 ms, as evidenced by the upper bound of a 95% one-sided confidence interval above 0.10, is the threshold for regulatory concern.</non_inferiority_desc>
            <param_type>Least-Squares Mean Double Delta Value</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>2.792</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Zoliflodacin administered at a 2 g dose causes a prolongation of the QTcF interval 6 h post-dose that exceeds the criteria in the ICH Guidance E14 (5 ms).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Per ICH E14, an increase in the QTcF interval of 5 ms, as evidenced by the upper bound of a 95% one-sided confidence interval above 0.10, is the threshold for regulatory concern.</non_inferiority_desc>
            <param_type>Least-Squares Mean Double Delta Value</param_type>
            <param_value>0.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>2.074</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Zoliflodacin administered at a 2 g dose causes a prolongation of the QTcF interval 8 h post-dose that exceeds the criteria in the ICH Guidance E14 (5 ms).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Per ICH E14, an increase in the QTcF interval of 5 ms, as evidenced by the upper bound of a 95% one-sided confidence interval above 0.10, is the threshold for regulatory concern.</non_inferiority_desc>
            <param_type>Least-Squares Mean Double Delta Value</param_type>
            <param_value>-0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>0.790</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Zoliflodacin administered at a 2 g dose causes a prolongation of the QTcF interval 12 h post-dose that exceeds the criteria in the ICH Guidance E14 (5 ms).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Per ICH E14, an increase in the QTcF interval of 5 ms, as evidenced by the upper bound of a 95% one-sided confidence interval above 0.10, is the threshold for regulatory concern.</non_inferiority_desc>
            <param_type>Least-Squares Mean Double Delta Value</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>1.650</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Zoliflodacin administered at a 2 g dose causes a prolongation of the QTcF interval 24 h post-dose that exceeds the criteria in the ICH Guidance E14 (5 ms).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Per ICH E14, an increase in the QTcF interval of 5 ms, as evidenced by the upper bound of a 95% one-sided confidence interval above 0.10, is the threshold for regulatory concern.</non_inferiority_desc>
            <param_type>Least-Squares Mean Double Delta Value</param_type>
            <param_value>-0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>1.131</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Zoliflodacin administered at a 4 g dose causes a prolongation of the QTcF interval 0.5 h post-dose that exceeds the criteria in the ICH Guidance E14 (5 ms).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Per ICH E14, an increase in the QTcF interval of 5 ms, as evidenced by the upper bound of a 95% one-sided confidence interval above 0.10, is the threshold for regulatory concern.</non_inferiority_desc>
            <param_type>Least-Squares Mean Double Delta Value</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>2.815</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Zoliflodacin administered at a 4 g dose causes a prolongation of the QTcF interval 1 h post-dose that exceeds the criteria in the ICH Guidance E14 (5 ms).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Per ICH E14, an increase in the QTcF interval of 5 ms, as evidenced by the upper bound of a 95% one-sided confidence interval above 0.10, is the threshold for regulatory concern.</non_inferiority_desc>
            <param_type>Least-Squares Mean Double Delta Value</param_type>
            <param_value>2.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>3.997</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Zoliflodacin administered at a 4 g dose causes a prolongation of the QTcF interval 2 h post-dose that exceeds the criteria in the ICH Guidance E14 (5 ms).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Per ICH E14, an increase in the QTcF interval of 5 ms, as evidenced by the upper bound of a 95% one-sided confidence interval above 0.10, is the threshold for regulatory concern.</non_inferiority_desc>
            <param_type>Least-Squares Mean Double Delta Value</param_type>
            <param_value>2.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>3.812</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Zoliflodacin administered at a 4 g dose causes a prolongation of the QTcF interval 3 h post-dose that exceeds the criteria in the ICH Guidance E14 (5 ms).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Per ICH E14, an increase in the QTcF interval of 5 ms, as evidenced by the upper bound of a 95% one-sided confidence interval above 0.10, is the threshold for regulatory concern.</non_inferiority_desc>
            <param_type>Least-Squares Mean Double Delta Value</param_type>
            <param_value>2.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>4.228</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Zoliflodacin administered at a 4 g dose causes a prolongation of the QTcF interval 4 h post-dose that exceeds the criteria in the ICH Guidance E14 (5 ms).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Per ICH E14, an increase in the QTcF interval of 5 ms, as evidenced by the upper bound of a 95% one-sided confidence interval above 0.10, is the threshold for regulatory concern.</non_inferiority_desc>
            <param_type>Least-Squares Mean Double Delta Value</param_type>
            <param_value>3.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>4.674</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Zoliflodacin administered at a 4 g dose causes a prolongation of the QTcF interval 6 h post-dose that exceeds the criteria in the ICH Guidance E14 (5 ms).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Per ICH E14, an increase in the QTcF interval of 5 ms, as evidenced by the upper bound of a 95% one-sided confidence interval above 0.10, is the threshold for regulatory concern.</non_inferiority_desc>
            <param_type>Least-Squares Mean Double Delta Value</param_type>
            <param_value>1.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>3.259</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Zoliflodacin administered at a 4 g dose causes a prolongation of the QTcF interval 8 h post-dose that exceeds the criteria in the ICH Guidance E14 (5 ms).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Per ICH E14, an increase in the QTcF interval of 5 ms, as evidenced by the upper bound of a 95% one-sided confidence interval above 0.10, is the threshold for regulatory concern.</non_inferiority_desc>
            <param_type>Least-Squares Mean Double Delta Value</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>1.566</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Zoliflodacin administered at a 4 g dose causes a prolongation of the QTcF interval 12 h post-dose that exceeds the criteria in the ICH Guidance E14 (5 ms).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Per ICH E14, an increase in the QTcF interval of 5 ms, as evidenced by the upper bound of a 95% one-sided confidence interval above 0.10, is the threshold for regulatory concern.</non_inferiority_desc>
            <param_type>Least-Squares Mean Double Delta Value</param_type>
            <param_value>1.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>3.459</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Zoliflodacin administered at a 4 g dose causes a prolongation of the QTcF interval 24 h post-dose that exceeds the criteria in the ICH Guidance E14 (5 ms).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Per ICH E14, an increase in the QTcF interval of 5 ms, as evidenced by the upper bound of a 95% one-sided confidence interval above 0.10, is the threshold for regulatory concern.</non_inferiority_desc>
            <param_type>Least-Squares Mean Double Delta Value</param_type>
            <param_value>1.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>3.415</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-matched, Placebo-corrected, Baseline-adjusted Heart Rate (HR) Following Administration of Zoliflodacin</title>
        <description>Mean and 90% two-sided confidence intervals (t-intervals) of change from baseline heart rate by time point and treatment. Note that the upper bound of the 90% two-sided confidence interval can also be interpreted as the upper bound of a 95% one-sided confidence interval.</description>
        <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
        <population>The analysis population sample size is equal to the number of subjects in the Holter ECG Analysis Population who received both a dose of zoliflodacin and a dose of placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of dosing period.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of dosing period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo was administered orally on Day 1 of dosing period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time-matched, Placebo-corrected, Baseline-adjusted Heart Rate (HR) Following Administration of Zoliflodacin</title>
          <description>Mean and 90% two-sided confidence intervals (t-intervals) of change from baseline heart rate by time point and treatment. Note that the upper bound of the 90% two-sided confidence interval can also be interpreted as the upper bound of a 95% one-sided confidence interval.</description>
          <population>The analysis population sample size is equal to the number of subjects in the Holter ECG Analysis Population who received both a dose of zoliflodacin and a dose of placebo.</population>
          <units>beats/minute</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="-0.50" upper_limit="1.24"/>
                    <measurement group_id="O2" value="2.2" lower_limit="1.36" upper_limit="2.94"/>
                    <measurement group_id="O3" value="0.1" lower_limit="-0.50" upper_limit="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.60" upper_limit="2.55"/>
                    <measurement group_id="O2" value="2.3" lower_limit="1.55" upper_limit="3.00"/>
                    <measurement group_id="O3" value="-0.6" lower_limit="-1.20" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.29" upper_limit="1.80"/>
                    <measurement group_id="O2" value="3.6" lower_limit="2.24" upper_limit="5.01"/>
                    <measurement group_id="O3" value="0.1" lower_limit="-0.62" upper_limit="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="1.35" upper_limit="3.00"/>
                    <measurement group_id="O2" value="4.5" lower_limit="3.05" upper_limit="5.95"/>
                    <measurement group_id="O3" value="0.7" lower_limit="-0.29" upper_limit="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.69" upper_limit="2.54"/>
                    <measurement group_id="O2" value="3.7" lower_limit="2.32" upper_limit="5.04"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-0.85" upper_limit="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="7.95" upper_limit="10.79"/>
                    <measurement group_id="O2" value="10.0" lower_limit="8.40" upper_limit="11.54"/>
                    <measurement group_id="O3" value="7.8" lower_limit="6.62" upper_limit="8.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="7.52" upper_limit="9.89"/>
                    <measurement group_id="O2" value="8.3" lower_limit="6.86" upper_limit="9.84"/>
                    <measurement group_id="O3" value="5.8" lower_limit="4.71" upper_limit="6.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="9.13" upper_limit="12.00"/>
                    <measurement group_id="O2" value="10.4" lower_limit="9.01" upper_limit="11.77"/>
                    <measurement group_id="O3" value="9.7" lower_limit="8.37" upper_limit="10.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1.60" upper_limit="3.37"/>
                    <measurement group_id="O2" value="2.8" lower_limit="1.66" upper_limit="3.85"/>
                    <measurement group_id="O3" value="3.4" lower_limit="2.20" upper_limit="4.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-matched, Placebo-corrected, Baseline-adjusted, the Time From the Onset of the P Wave to the Start of the QRS Complex (PR Interval) Following Administration of Zoliflodacin</title>
        <description>Mean and 90% two-sided confidence intervals (t-intervals) of change from baseline PR intervals by time point and treatment. Note that the upper bound of the 90% two-sided confidence interval can also be interpreted as the upper bound of a 95% one-sided confidence interval.</description>
        <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
        <population>The analysis population sample size is equal to the number of subjects in the Holter ECG Analysis Population who received both a dose of zoliflodacin and a dose of placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of dosing period.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of dosing period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo was administered orally on Day 1 of dosing period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time-matched, Placebo-corrected, Baseline-adjusted, the Time From the Onset of the P Wave to the Start of the QRS Complex (PR Interval) Following Administration of Zoliflodacin</title>
          <description>Mean and 90% two-sided confidence intervals (t-intervals) of change from baseline PR intervals by time point and treatment. Note that the upper bound of the 90% two-sided confidence interval can also be interpreted as the upper bound of a 95% one-sided confidence interval.</description>
          <population>The analysis population sample size is equal to the number of subjects in the Holter ECG Analysis Population who received both a dose of zoliflodacin and a dose of placebo.</population>
          <units>milliseconds (msec)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" lower_limit="-1.90" upper_limit="0.53"/>
                    <measurement group_id="O2" value="-1.1" lower_limit="-2.01" upper_limit="-0.24"/>
                    <measurement group_id="O3" value="-0.3" lower_limit="-1.35" upper_limit="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" lower_limit="-2.04" upper_limit="0.33"/>
                    <measurement group_id="O2" value="-2.3" lower_limit="-3.31" upper_limit="-1.35"/>
                    <measurement group_id="O3" value="0.2" lower_limit="-0.70" upper_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" lower_limit="-2.69" upper_limit="-0.47"/>
                    <measurement group_id="O2" value="-1.8" lower_limit="-3.09" upper_limit="-0.49"/>
                    <measurement group_id="O3" value="-0.2" lower_limit="-1.11" upper_limit="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" lower_limit="-4.11" upper_limit="-1.02"/>
                    <measurement group_id="O2" value="-2.9" lower_limit="-4.17" upper_limit="-1.65"/>
                    <measurement group_id="O3" value="-1.1" lower_limit="-2.24" upper_limit="-0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" lower_limit="-4.00" upper_limit="-1.52"/>
                    <measurement group_id="O2" value="-3.2" lower_limit="-4.35" upper_limit="-1.95"/>
                    <measurement group_id="O3" value="-0.6" lower_limit="-1.68" upper_limit="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" lower_limit="-5.60" upper_limit="-1.69"/>
                    <measurement group_id="O2" value="-3.9" lower_limit="-5.43" upper_limit="-2.45"/>
                    <measurement group_id="O3" value="-1.8" lower_limit="-3.39" upper_limit="-0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" lower_limit="-7.43" upper_limit="-4.03"/>
                    <measurement group_id="O2" value="-5.4" lower_limit="-6.80" upper_limit="-4.05"/>
                    <measurement group_id="O3" value="-5.3" lower_limit="-6.81" upper_limit="-3.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" lower_limit="-4.69" upper_limit="-1.40"/>
                    <measurement group_id="O2" value="-3.5" lower_limit="-4.63" upper_limit="-2.41"/>
                    <measurement group_id="O3" value="-4.3" lower_limit="-5.78" upper_limit="-2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" lower_limit="-2.88" upper_limit="-0.49"/>
                    <measurement group_id="O2" value="-0.8" lower_limit="-2.01" upper_limit="0.38"/>
                    <measurement group_id="O3" value="-0.7" lower_limit="-1.83" upper_limit="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-matched, Placebo-corrected, Baseline-adjusted the Time Elapsed Between Two Successive R Waves of the QRS (RR Interval) Following Administration of Zoliflodacin</title>
        <description>Mean and 90% two-sided confidence intervals (t-intervals) of change from baseline RR intervals by time point and treatment. Note that the upper bound of the 90% two-sided confidence interval can also be interpreted as the upper bound of a 95% one-sided confidence interval.</description>
        <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
        <population>The analysis population sample size is equal to the number of subjects in the Holter ECG Analysis Population who received both a dose of zoliflodacin and a dose of placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of dosing period.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of dosing period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo was administered orally on Day 1 of dosing period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time-matched, Placebo-corrected, Baseline-adjusted the Time Elapsed Between Two Successive R Waves of the QRS (RR Interval) Following Administration of Zoliflodacin</title>
          <description>Mean and 90% two-sided confidence intervals (t-intervals) of change from baseline RR intervals by time point and treatment. Note that the upper bound of the 90% two-sided confidence interval can also be interpreted as the upper bound of a 95% one-sided confidence interval.</description>
          <population>The analysis population sample size is equal to the number of subjects in the Holter ECG Analysis Population who received both a dose of zoliflodacin and a dose of placebo.</population>
          <units>milliseconds (msec)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" lower_limit="-18.87" upper_limit="7.20"/>
                    <measurement group_id="O2" value="-33.5" lower_limit="-46.70" upper_limit="-20.39"/>
                    <measurement group_id="O3" value="-1.2" lower_limit="-11.70" upper_limit="9.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.6" lower_limit="-36.30" upper_limit="-8.81"/>
                    <measurement group_id="O2" value="-35.0" lower_limit="-46.45" upper_limit="-23.58"/>
                    <measurement group_id="O3" value="9.7" lower_limit="-0.72" upper_limit="20.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.8" lower_limit="-25.30" upper_limit="-2.32"/>
                    <measurement group_id="O2" value="-51.0" lower_limit="-65.99" upper_limit="-36.07"/>
                    <measurement group_id="O3" value="3.0" lower_limit="-9.34" upper_limit="15.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.0" lower_limit="-43.54" upper_limit="-20.52"/>
                    <measurement group_id="O2" value="-63.1" lower_limit="-80.01" upper_limit="-46.21"/>
                    <measurement group_id="O3" value="-10.1" lower_limit="-24.26" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.3" lower_limit="-35.96" upper_limit="-10.57"/>
                    <measurement group_id="O2" value="-47.6" lower_limit="-64.48" upper_limit="-30.73"/>
                    <measurement group_id="O3" value="-0.7" lower_limit="-15.60" upper_limit="14.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-127.1" lower_limit="-144.51" upper_limit="-109.67"/>
                    <measurement group_id="O2" value="-133.0" lower_limit="-152.59" upper_limit="-113.50"/>
                    <measurement group_id="O3" value="-113.7" lower_limit="-130.03" upper_limit="-97.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-120.2" lower_limit="-135.53" upper_limit="-104.88"/>
                    <measurement group_id="O2" value="-111.0" lower_limit="-127.57" upper_limit="-94.37"/>
                    <measurement group_id="O3" value="-87.5" lower_limit="-102.32" upper_limit="-72.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-141.2" lower_limit="-159.18" upper_limit="-123.21"/>
                    <measurement group_id="O2" value="-139.8" lower_limit="-155.48" upper_limit="-124.06"/>
                    <measurement group_id="O3" value="-140.5" lower_limit="-159.15" upper_limit="-121.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.4" lower_limit="-49.72" upper_limit="-25.05"/>
                    <measurement group_id="O2" value="-41.2" lower_limit="-57.11" upper_limit="-25.25"/>
                    <measurement group_id="O3" value="-50.2" lower_limit="-65.39" upper_limit="-35.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-matched, Placebo-corrected, Baseline-adjusted QRS Duration Following Administration of Zoliflodacin</title>
        <description>Mean and 90% two-sided confidence intervals (t-intervals) of change from baseline QRS durations by time point and treatment. Note that the upper bound of the 90% two-sided confidence interval can also be interpreted as the upper bound of a 95% one-sided confidence interval.</description>
        <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
        <population>The analysis population sample size is equal to the number of subjects in the Holter ECG Analysis Population who received both a dose of zoliflodacin and a dose of placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of dosing period.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of dosing period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo was administered orally on Day 1 of dosing period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time-matched, Placebo-corrected, Baseline-adjusted QRS Duration Following Administration of Zoliflodacin</title>
          <description>Mean and 90% two-sided confidence intervals (t-intervals) of change from baseline QRS durations by time point and treatment. Note that the upper bound of the 90% two-sided confidence interval can also be interpreted as the upper bound of a 95% one-sided confidence interval.</description>
          <population>The analysis population sample size is equal to the number of subjects in the Holter ECG Analysis Population who received both a dose of zoliflodacin and a dose of placebo.</population>
          <units>milliseconds (msec)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-0.60" upper_limit="0.07"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-0.45" upper_limit="0.24"/>
                    <measurement group_id="O3" value="-0.3" lower_limit="-0.63" upper_limit="-0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-0.87" upper_limit="-0.16"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-0.23" upper_limit="0.38"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-0.28" upper_limit="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" lower_limit="-0.91" upper_limit="-0.25"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-0.90" upper_limit="-0.20"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-0.47" upper_limit="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-0.70" upper_limit="-0.08"/>
                    <measurement group_id="O2" value="-0.4" lower_limit="-0.72" upper_limit="-0.07"/>
                    <measurement group_id="O3" value="-0.1" lower_limit="-0.35" upper_limit="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-0.82" upper_limit="-0.19"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-0.57" upper_limit="0.12"/>
                    <measurement group_id="O3" value="-0.1" lower_limit="-0.50" upper_limit="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-0.34" upper_limit="0.49"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-0.25" upper_limit="0.49"/>
                    <measurement group_id="O3" value="0.8" lower_limit="0.43" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" lower_limit="-1.03" upper_limit="-0.28"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-1.08" upper_limit="-0.26"/>
                    <measurement group_id="O3" value="-0.3" lower_limit="-0.69" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-0.79" upper_limit="0.02"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-0.77" upper_limit="-0.15"/>
                    <measurement group_id="O3" value="-0.3" lower_limit="-0.66" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-0.89" upper_limit="-0.12"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-0.61" upper_limit="0.18"/>
                    <measurement group_id="O3" value="-0.4" lower_limit="-0.67" upper_limit="-0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The One-sided 95% Confidence Interval (CI) of the Time-matched, Placebo-corrected, Baseline-adjusted Mean QTcF Interval (Delta Delta QTcF) After a Single Dose of Moxifloxacin</title>
        <description>Mean and 90% two-sided confidence intervals (t-intervals) of change from baseline QTcF intervals by time point and treatment. Note that the upper bound of the 90% two-sided confidence interval can also be interpreted as the upper bound of a 95% one-sided confidence interval.</description>
        <time_frame>Baseline, 1 h, 2 h, 3 h, and 4 h post-dose</time_frame>
        <population>Any participants who received a dose of moxifloxacin and placebo and had post dose assessments is counted in the population.</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg of Moxifloxacin</title>
            <description>400 mg of moxifloxacin administered orally on Day 1 of dosing period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered orally on Day 1 of dosing period.</description>
          </group>
        </group_list>
        <measure>
          <title>The One-sided 95% Confidence Interval (CI) of the Time-matched, Placebo-corrected, Baseline-adjusted Mean QTcF Interval (Delta Delta QTcF) After a Single Dose of Moxifloxacin</title>
          <description>Mean and 90% two-sided confidence intervals (t-intervals) of change from baseline QTcF intervals by time point and treatment. Note that the upper bound of the 90% two-sided confidence interval can also be interpreted as the upper bound of a 95% one-sided confidence interval.</description>
          <population>Any participants who received a dose of moxifloxacin and placebo and had post dose assessments is counted in the population.</population>
          <units>milliseconds (msec)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="6.81" upper_limit="8.99"/>
                    <measurement group_id="O2" value="-2.3" lower_limit="-3.34" upper_limit="-1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="7.32" upper_limit="9.59"/>
                    <measurement group_id="O2" value="-2.2" lower_limit="-3.30" upper_limit="-1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="6.67" upper_limit="9.36"/>
                    <measurement group_id="O2" value="-2.6" lower_limit="-3.78" upper_limit="-1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" lower_limit="5.93" upper_limit="8.53"/>
                    <measurement group_id="O2" value="-3.3" lower_limit="-4.36" upper_limit="-2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: The trial does not have the sensitivity to detect an effect on QTcF of regulatory concern, as produced by 400 mg moxifloxacin 1 h after dose.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>According to ICH E14, &quot;the positive control should have an effect on the mean QT/QTc interval of about 5 ms.&quot; Comparison of the lower bound of the confidence interval to 5 ms for a 400 mg dose of moxifloxacin is standard practice for demonstrating assay sensitivity in thorough QT studies.</non_inferiority_desc>
            <param_type>Least-Squares Mean Double Delta Value</param_type>
            <param_value>10.19</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>8.257</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: The trial does not have the sensitivity to detect an effect on QTcF of regulatory concern, as produced by 400 mg moxifloxacin 2 h after dose.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>According to ICH E14, &quot;the positive control should have an effect on the mean QT/QTc interval of about 5 ms.&quot; Comparison of the lower bound of the confidence interval to 5 ms for a 400 mg dose of moxifloxacin is standard practice for demonstrating assay sensitivity in thorough QT studies.</non_inferiority_desc>
            <param_type>Least-Squares Mean Double Delta Value</param_type>
            <param_value>10.79</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>8.860</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: The trial does not have the sensitivity to detect an effect on QTcF of regulatory concern, as produced by 400 mg moxifloxacin 3 h after dose.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>According to ICH E14, &quot;the positive control should have an effect on the mean QT/QTc interval of about 5 ms.&quot; Comparison of the lower bound of the confidence interval to 5 ms for a 400 mg dose of moxifloxacin is standard practice for demonstrating assay sensitivity in thorough QT studies.</non_inferiority_desc>
            <param_type>Least-Squares Mean Double Delta Value</param_type>
            <param_value>10.62</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>8.683</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: The trial does not have the sensitivity to detect an effect on QTcF of regulatory concern, as produced by 400 mg moxifloxacin 4 h after dose.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>According to ICH E14, &quot;the positive control should have an effect on the mean QT/QTc interval of about 5 ms.&quot; Comparison of the lower bound of the confidence interval to 5 ms for a 400 mg dose of moxifloxacin is standard practice for demonstrating assay sensitivity in thorough QT studies.</non_inferiority_desc>
            <param_type>Least-Squares Mean Double Delta Value</param_type>
            <param_value>10.63</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>8.698</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Abnormal T-wave Morphology Following Administration of Zoliflodacin</title>
        <description>Categorical T-wave morphology analysis was collected in three ECG replicates at each timepoint (Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose). Abnormalities present in any one or more of the baseline timepoint replicate ECGs recorded for a particular period was considered to be present at baseline for post-dose ECGs from that specific period. If a subject had an ECG morphological abnormality in more than one replicate ECG of a study timepoint, the subject was counted only once for that timepoint. Flat is defined as T amplitude &lt;1 mm (either positive or negative) including flat isoelectric line and Biphasic is defined as T-wave that contains a second component with an opposite phase that was at least 0.1 millivolts (mV) deep (both positive and negative/positive and polyphasic T-waves included).</description>
        <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
        <population>Any participants who received study product and had post dose assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for zoliflodacin administered orally on Day 1 of each dosing period
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.</description>
          </group>
          <group group_id="O2">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O3">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O4">
            <title>400 mg of Moxifloxacin</title>
            <description>400 mg of moxifloxacin administered orally on Day 1 of each dosing period
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Abnormal T-wave Morphology Following Administration of Zoliflodacin</title>
          <description>Categorical T-wave morphology analysis was collected in three ECG replicates at each timepoint (Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose). Abnormalities present in any one or more of the baseline timepoint replicate ECGs recorded for a particular period was considered to be present at baseline for post-dose ECGs from that specific period. If a subject had an ECG morphological abnormality in more than one replicate ECG of a study timepoint, the subject was counted only once for that timepoint. Flat is defined as T amplitude &lt;1 mm (either positive or negative) including flat isoelectric line and Biphasic is defined as T-wave that contains a second component with an opposite phase that was at least 0.1 millivolts (mV) deep (both positive and negative/positive and polyphasic T-waves included).</description>
          <population>Any participants who received study product and had post dose assessments.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 h post dose: T wave: Abnormal, Biphasic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 h post dose: T wave: Abnormal, Flat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 h post: T wave:Abnormal, Inverted, Asymmetric</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h post dose: T wave: Abnormal, Biphasic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h post dose: T wave: Abnormal, Flat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h post: T wave: Abnormal, Inverted, Asymmetric</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h post dose: T wave: Abnormal, Biphasic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h post dose: T wave: Abnormal, Flat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h post: T wave: Abnormal, Inverted, Asymmetric</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 h post dose: T wave: Abnormal, Biphasic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 h post dose: T wave: Abnormal, Flat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 h post:T wave: Abnormal, Inverted, Asymmetric</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h post dose: T wave: Abnormal, Biphasic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h post dose: T wave: Abnormal, Flat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h post:T wave: Abnormal, Inverted, Asymmetric</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 h post dose: T wave: Abnormal, Biphasic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 h post dose: T wave: Abnormal, Flat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 h post:T wave: Abnormal, Inverted, Asymmetric</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 h post dose: T wave: Abnormal, Biphasic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 h post dose: T wave: Abnormal, Flat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 h post:T wave: Abnormal, Inverted, Asymmetric</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 h post dose: T wave: Abnormal, Biphasic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 h post dose: T wave: Abnormal, Flat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 h post:T wave: Abnormal, Inverted, Asymmetric</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h post dose: T wave: Abnormal, Biphasic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="65"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h post dose: T wave: Abnormal, Flat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="65"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h post:T wave: Abnormal, Inverted, Asymmetric</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="65"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Concentration (Cmax) of Zoliflodacin</title>
        <description>Cmax is defined as the maximum observed drug concentration observed in plasma over all PK sample concentrations computed from concentrations that were measured using a validated HPLC-MS/MS method. Pharmacokinetic (PK) parameters were computed using plasma concentrations from samples collected pre-dose and intervals post-dose.</description>
        <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) of Zoliflodacin</title>
          <description>Cmax is defined as the maximum observed drug concentration observed in plasma over all PK sample concentrations computed from concentrations that were measured using a validated HPLC-MS/MS method. Pharmacokinetic (PK) parameters were computed using plasma concentrations from samples collected pre-dose and intervals post-dose.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12120" spread="2985"/>
                    <measurement group_id="O2" value="20350" spread="8682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Maximum Observed Concentration (Tmax) of Zoliflodacin</title>
        <description>Tmax is defined as the time at which the maximum concentration (Cmax) occurs in plasma computed from concentrations that were measured using a validated HPLC-MS/MS method. PK parameters were computed using plasma concentrations from samples collected pre-dose and intervals post-dose.</description>
        <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Observed Concentration (Tmax) of Zoliflodacin</title>
          <description>Tmax is defined as the time at which the maximum concentration (Cmax) occurs in plasma computed from concentrations that were measured using a validated HPLC-MS/MS method. PK parameters were computed using plasma concentrations from samples collected pre-dose and intervals post-dose.</description>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.90" spread="1.08"/>
                    <measurement group_id="O2" value="3.03" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Time-curve From Time Zero to Infinity (AUC(0 - Infinity)) for Zoliflodacin</title>
        <description>AUC(0 - infinity) was defined as the total area under the concentration-time curve from dosing (time 0) taken to the limit as the end time becomes arbitrarily large. AUC(0 - infinity) was calculated by adding AUC(0-last) to an extrapolated value equal to the last measured concentration greater than the lower limit of quantification of the bioanalytical assay divided by the terminal phase elimination rate constant (Ke) computed from concentrations that were measured using a validated HPLC-MS/MS method. PK parameters were computed using plasma concentrations from samples collected pre-dose and intervals post-dose.</description>
        <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time-curve From Time Zero to Infinity (AUC(0 - Infinity)) for Zoliflodacin</title>
          <description>AUC(0 - infinity) was defined as the total area under the concentration-time curve from dosing (time 0) taken to the limit as the end time becomes arbitrarily large. AUC(0 - infinity) was calculated by adding AUC(0-last) to an extrapolated value equal to the last measured concentration greater than the lower limit of quantification of the bioanalytical assay divided by the terminal phase elimination rate constant (Ke) computed from concentrations that were measured using a validated HPLC-MS/MS method. PK parameters were computed using plasma concentrations from samples collected pre-dose and intervals post-dose.</description>
          <units>h x ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108300" spread="32980"/>
                    <measurement group_id="O2" value="181400" spread="52890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Time-curve From Time Zero to the Last Concentration Above the Lower Limit of Quantitation (AUC(0-last)) for Zoliflodacin</title>
        <description>AUC(0-last) was defined as the area under the concentration-time curve from dosing (time 0) to the time of the last measured concentration computed from concentrations that were measured using a validated HPLC-MS/MS method. PK parameters were computed using plasma concentrations from samples collected pre-dose and intervals post-dose.</description>
        <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time-curve From Time Zero to the Last Concentration Above the Lower Limit of Quantitation (AUC(0-last)) for Zoliflodacin</title>
          <description>AUC(0-last) was defined as the area under the concentration-time curve from dosing (time 0) to the time of the last measured concentration computed from concentrations that were measured using a validated HPLC-MS/MS method. PK parameters were computed using plasma concentrations from samples collected pre-dose and intervals post-dose.</description>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102700" spread="28580"/>
                    <measurement group_id="O2" value="177300" spread="52370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz/F) of Zoliflodacin</title>
        <description>Apparent volume of distribution during terminal phase (Vz/F) after non-intravenous administration was calculated as (CL/F)/ Ke computed from concentrations that were measured using a validated HPLC-MS/MS method. PK parameters were computed using plasma concentrations from samples collected pre-dose and intervals post-dose.</description>
        <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/F) of Zoliflodacin</title>
          <description>Apparent volume of distribution during terminal phase (Vz/F) after non-intravenous administration was calculated as (CL/F)/ Ke computed from concentrations that were measured using a validated HPLC-MS/MS method. PK parameters were computed using plasma concentrations from samples collected pre-dose and intervals post-dose.</description>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.55" spread="50.46"/>
                    <measurement group_id="O2" value="204.29" spread="55.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Oral Clearance (CL/F) of Zoliflodacin</title>
        <description>Apparent oral clearance (CL/F) computed as Dose/Area under the curve (AUC) from time zero to infinity (0-infinity) computed from concentrations that were measured using a validated high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method. PK parameters were computed using plasma concentrations from samples collected pre-dose and intervals post-dose.</description>
        <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Oral Clearance (CL/F) of Zoliflodacin</title>
          <description>Apparent oral clearance (CL/F) computed as Dose/Area under the curve (AUC) from time zero to infinity (0-infinity) computed from concentrations that were measured using a validated high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method. PK parameters were computed using plasma concentrations from samples collected pre-dose and intervals post-dose.</description>
          <units>Liter/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.08" spread="5.74"/>
                    <measurement group_id="O2" value="23.77" spread="6.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Rate Constant (Ke) of Zoliflodacin</title>
        <description>The terminal phase elimination rate constant (Ke) was defined as the first-order rate constant describing the rate of decrease of drug concentration in the terminal phase (defined as the terminal region of the PK curve where drug concentration follows first-order elimination kinetics) computed from concentrations that were measured using a validated HPLC-MS/MS method. PK parameters were computed using plasma concentrations from samples collected pre-dose and intervals post-dose.</description>
        <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Rate Constant (Ke) of Zoliflodacin</title>
          <description>The terminal phase elimination rate constant (Ke) was defined as the first-order rate constant describing the rate of decrease of drug concentration in the terminal phase (defined as the terminal region of the PK curve where drug concentration follows first-order elimination kinetics) computed from concentrations that were measured using a validated HPLC-MS/MS method. PK parameters were computed using plasma concentrations from samples collected pre-dose and intervals post-dose.</description>
          <units>1/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1267" spread="0.01590"/>
                    <measurement group_id="O2" value="0.1174" spread="0.01467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-life (t1/2) of Zoliflodacin</title>
        <description>The apparent terminal elimination half-life (t1/2) was defined as the time required for the drug concentration to decrease by a factor of one-half in the terminal phase computed from concentrations that were measured using a validated HPLC-MS/MS method. PK parameters were computed using plasma concentrations from samples collected pre-dose and intervals post-dose.</description>
        <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (t1/2) of Zoliflodacin</title>
          <description>The apparent terminal elimination half-life (t1/2) was defined as the time required for the drug concentration to decrease by a factor of one-half in the terminal phase computed from concentrations that were measured using a validated HPLC-MS/MS method. PK parameters were computed using plasma concentrations from samples collected pre-dose and intervals post-dose.</description>
          <units>Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.55" spread="0.67"/>
                    <measurement group_id="O2" value="5.99" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Plasma Concentrations of Zoliflodacin and Time-matched, Placebo-corrected, Baseline-adjusted Mean QTcF Interval (Delta Delta QTcF) Following Administration of Zoliflodacin</title>
        <description>One-sided 95% confidence intervals of population mean QTcF time-matched, placebo-corrected, baseline-adjusted mean QTcF interval at plasma concentration corresponding to the observed geometric mean Cmax for 2 g and 4 g doses of zoliflodacin were computed using a linear mixed effect model with PK and concentration data collected at baseline and intervals post-dose.</description>
        <time_frame>Baseline, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose</time_frame>
        <population>Any participants who received study product and had post dose assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Plasma Concentrations of Zoliflodacin and Time-matched, Placebo-corrected, Baseline-adjusted Mean QTcF Interval (Delta Delta QTcF) Following Administration of Zoliflodacin</title>
          <description>One-sided 95% confidence intervals of population mean QTcF time-matched, placebo-corrected, baseline-adjusted mean QTcF interval at plasma concentration corresponding to the observed geometric mean Cmax for 2 g and 4 g doses of zoliflodacin were computed using a linear mixed effect model with PK and concentration data collected at baseline and intervals post-dose.</description>
          <population>Any participants who received study product and had post dose assessments.</population>
          <units>milliseconds (msec)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="NA" upper_limit="2.54">The NA values shown in the lower bounds are a stand-in for negative infinity (-8).</measurement>
                    <measurement group_id="O2" value="3.0" lower_limit="NA" upper_limit="4.41">The NA values shown in the lower bounds are a stand-in for negative infinity (-8).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Serious Adverse Events Following Administration of Zoliflodacin and Moxifloxacin</title>
        <description>Serious adverse events included any untoward medical occurrence that resulted in death; was life threatening; was a persistent/significant disability/incapacity; required inpatient hospitalization or prolongation or a congenital anomaly/birth defect.</description>
        <time_frame>From study product administration (Day 1) through prior to the next dose (Day 8 or Final visit).</time_frame>
        <population>Any participants who received study product.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for zoliflodacin administered orally on Day 1 of each dosing period
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.</description>
          </group>
          <group group_id="O4">
            <title>400 mg of Moxifloxacin</title>
            <description>400 mg of moxifloxacin administered orally on Day 1 of each dosing period
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Serious Adverse Events Following Administration of Zoliflodacin and Moxifloxacin</title>
          <description>Serious adverse events included any untoward medical occurrence that resulted in death; was life threatening; was a persistent/significant disability/incapacity; required inpatient hospitalization or prolongation or a congenital anomaly/birth defect.</description>
          <population>Any participants who received study product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events Following Administration of Study Product</title>
        <description>Adverse events are defined as any untoward medical occurrence regardless of its causal relationship to the study treatment.</description>
        <time_frame>From study product administration (Day 1) through prior to the next dose (Day 8 or Final visit).</time_frame>
        <population>Any participants who received study product.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for zoliflodacin administered orally on Day 1 of each dosing period
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.</description>
          </group>
          <group group_id="O4">
            <title>400 mg of Moxifloxacin</title>
            <description>400 mg of moxifloxacin administered orally on Day 1 of each dosing period
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events Following Administration of Study Product</title>
          <description>Adverse events are defined as any untoward medical occurrence regardless of its causal relationship to the study treatment.</description>
          <population>Any participants who received study product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline for Blood Pressure - Systolic</title>
        <description>Change from baseline in systolic blood pressure was calculated by subtracting the baseline (pre-dose) measurement from the post-dose measurement. Post-dose measurements were taken 1 h, 2 h, 4 h and 24 h after dosing. Follow up is defined as the check in visit for the next dosing period or the final visit.</description>
        <time_frame>From study product administration (Day 1) through prior to the next dose (Day 8 or Final visit).</time_frame>
        <population>Any participants who received study product and had post dose assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for zoliflodacin administered orally on Day 1 of each dosing period
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.</description>
          </group>
          <group group_id="O4">
            <title>400 mg of Moxifloxacin</title>
            <description>400 mg of moxifloxacin administered orally on Day 1 of each dosing period
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline for Blood Pressure - Systolic</title>
          <description>Change from baseline in systolic blood pressure was calculated by subtracting the baseline (pre-dose) measurement from the post-dose measurement. Post-dose measurements were taken 1 h, 2 h, 4 h and 24 h after dosing. Follow up is defined as the check in visit for the next dosing period or the final visit.</description>
          <population>Any participants who received study product and had post dose assessments.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="7.3"/>
                    <measurement group_id="O2" value="1.3" spread="7.9"/>
                    <measurement group_id="O3" value="0.8" spread="7.6"/>
                    <measurement group_id="O4" value="0.4" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="8.0"/>
                    <measurement group_id="O2" value="-0.3" spread="7.6"/>
                    <measurement group_id="O3" value="1.0" spread="8.6"/>
                    <measurement group_id="O4" value="-0.5" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="7.1"/>
                    <measurement group_id="O2" value="-0.9" spread="7.5"/>
                    <measurement group_id="O3" value="1.0" spread="7.6"/>
                    <measurement group_id="O4" value="-1.7" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="8.2"/>
                    <measurement group_id="O2" value="-0.4" spread="7.8"/>
                    <measurement group_id="O3" value="1.1" spread="7.3"/>
                    <measurement group_id="O4" value="0.5" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="8.2"/>
                    <measurement group_id="O2" value="2.3" spread="6.9"/>
                    <measurement group_id="O3" value="3.7" spread="9.2"/>
                    <measurement group_id="O4" value="5.0" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline for Blood Pressure - Diastolic</title>
        <description>Change from baseline in diastolic blood pressure was calculated by subtracting the baseline (pre-dose) measurement from the post-dose measurement. Post-dose measurements were taken 1 h, 2 h, 4 h and 24 h after dosing. Follow up is defined as the check in visit for the next dosing period or the final visit.</description>
        <time_frame>From study product administration (Day 1) through prior to the next dose (Day 8 or Final visit).</time_frame>
        <population>Any participants who received study product and had post dose assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for zoliflodacin administered orally on Day 1 of each dosing period
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.</description>
          </group>
          <group group_id="O4">
            <title>400 mg of Moxifloxacin</title>
            <description>400 mg of moxifloxacin administered orally on Day 1 of each dosing period
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline for Blood Pressure - Diastolic</title>
          <description>Change from baseline in diastolic blood pressure was calculated by subtracting the baseline (pre-dose) measurement from the post-dose measurement. Post-dose measurements were taken 1 h, 2 h, 4 h and 24 h after dosing. Follow up is defined as the check in visit for the next dosing period or the final visit.</description>
          <population>Any participants who received study product and had post dose assessments.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="5.3"/>
                    <measurement group_id="O2" value="0.3" spread="4.8"/>
                    <measurement group_id="O3" value="0.8" spread="6.1"/>
                    <measurement group_id="O4" value="1.5" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="6.0"/>
                    <measurement group_id="O2" value="-0.9" spread="5.1"/>
                    <measurement group_id="O3" value="0.6" spread="6.7"/>
                    <measurement group_id="O4" value="1.2" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="4.9"/>
                    <measurement group_id="O2" value="-2.3" spread="5.3"/>
                    <measurement group_id="O3" value="1.1" spread="5.7"/>
                    <measurement group_id="O4" value="-0.1" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="5.3"/>
                    <measurement group_id="O2" value="-0.5" spread="5.7"/>
                    <measurement group_id="O3" value="1.4" spread="5.4"/>
                    <measurement group_id="O4" value="1.1" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="5.3"/>
                    <measurement group_id="O2" value="0.5" spread="5.5"/>
                    <measurement group_id="O3" value="2.7" spread="6.7"/>
                    <measurement group_id="O4" value="3.8" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline for Pulse Rate</title>
        <description>Change from baseline in pulse rate was calculated by subtracting the baseline (pre-dose) measurement from the post-dose measurement. Post-dose measurements were taken 1 h, 2 h, 4 h and 24 h after dosing. Follow up is defined as the check in visit for the next dosing period or the final visit.</description>
        <time_frame>From study product administration (Day 1) through prior to the next dose (Day 8 or Final visit).</time_frame>
        <population>Any participants who received study product and had post dose assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for zoliflodacin administered orally on Day 1 of each dosing period
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.</description>
          </group>
          <group group_id="O4">
            <title>400 mg of Moxifloxacin</title>
            <description>400 mg of moxifloxacin administered orally on Day 1 of each dosing period
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline for Pulse Rate</title>
          <description>Change from baseline in pulse rate was calculated by subtracting the baseline (pre-dose) measurement from the post-dose measurement. Post-dose measurements were taken 1 h, 2 h, 4 h and 24 h after dosing. Follow up is defined as the check in visit for the next dosing period or the final visit.</description>
          <population>Any participants who received study product and had post dose assessments.</population>
          <units>beats/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="8.3"/>
                    <measurement group_id="O2" value="5.7" spread="7.8"/>
                    <measurement group_id="O3" value="2.8" spread="8.1"/>
                    <measurement group_id="O4" value="6.9" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="7.8"/>
                    <measurement group_id="O2" value="6.5" spread="8.0"/>
                    <measurement group_id="O3" value="3.8" spread="7.5"/>
                    <measurement group_id="O4" value="5.5" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="8.5"/>
                    <measurement group_id="O2" value="5.8" spread="8.3"/>
                    <measurement group_id="O3" value="3.0" spread="9.6"/>
                    <measurement group_id="O4" value="5.2" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="7.7"/>
                    <measurement group_id="O2" value="5.2" spread="7.3"/>
                    <measurement group_id="O3" value="5.4" spread="8.4"/>
                    <measurement group_id="O4" value="6.3" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="8.7"/>
                    <measurement group_id="O2" value="2.8" spread="7.7"/>
                    <measurement group_id="O3" value="2.0" spread="10.3"/>
                    <measurement group_id="O4" value="4.2" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline for Respiratory Rate</title>
        <description>Change from baseline in respiratory rate was calculated by subtracting the baseline (pre-dose) measurement from the post-dose measurement. Post-dose measurements were taken 1 h, 2 h, 4 h and 24 h after dosing. Follow up is defined as the check in visit for the next dosing period or the final visit.</description>
        <time_frame>From study product administration (Day 1) through prior to the next dose (Day 8 or Final visit).</time_frame>
        <population>Any participants who received study product and had post dose assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for zoliflodacin administered orally on Day 1 of each dosing period
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.</description>
          </group>
          <group group_id="O4">
            <title>400 mg of Moxifloxacin</title>
            <description>400 mg of moxifloxacin administered orally on Day 1 of each dosing period
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline for Respiratory Rate</title>
          <description>Change from baseline in respiratory rate was calculated by subtracting the baseline (pre-dose) measurement from the post-dose measurement. Post-dose measurements were taken 1 h, 2 h, 4 h and 24 h after dosing. Follow up is defined as the check in visit for the next dosing period or the final visit.</description>
          <population>Any participants who received study product and had post dose assessments.</population>
          <units>breaths/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="3.1"/>
                    <measurement group_id="O2" value="1.1" spread="2.9"/>
                    <measurement group_id="O3" value="1.0" spread="2.8"/>
                    <measurement group_id="O4" value="0.4" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="3.2"/>
                    <measurement group_id="O2" value="0.7" spread="2.9"/>
                    <measurement group_id="O3" value="-0.3" spread="3.0"/>
                    <measurement group_id="O4" value="0.0" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="3.6"/>
                    <measurement group_id="O2" value="1.3" spread="3.3"/>
                    <measurement group_id="O3" value="-0.2" spread="2.7"/>
                    <measurement group_id="O4" value="0.1" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="3.1"/>
                    <measurement group_id="O2" value="1.0" spread="2.9"/>
                    <measurement group_id="O3" value="0.6" spread="2.7"/>
                    <measurement group_id="O4" value="0.5" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="3.1"/>
                    <measurement group_id="O2" value="1.3" spread="3.3"/>
                    <measurement group_id="O3" value="0.2" spread="3.0"/>
                    <measurement group_id="O4" value="0.6" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline for Temperature</title>
        <description>Change from baseline for temperature was calculated by subtracting the baseline (pre-dose) measurement from the post-dose measurement. Post-dose measurements were taken 1 h, 2 h, 4 h and 24 h after dosing. Follow up is defined as the check in visit for the next dosing period or the final visit.</description>
        <time_frame>From study product administration (Day 1) through prior to the next dose (Day 8 or Final visit).</time_frame>
        <population>Any participants who received study product and had post dose assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for zoliflodacin administered orally on Day 1 of each dosing period
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.</description>
          </group>
          <group group_id="O4">
            <title>400 mg of Moxifloxacin</title>
            <description>400 mg of moxifloxacin administered orally on Day 1 of each dosing period
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline for Temperature</title>
          <description>Change from baseline for temperature was calculated by subtracting the baseline (pre-dose) measurement from the post-dose measurement. Post-dose measurements were taken 1 h, 2 h, 4 h and 24 h after dosing. Follow up is defined as the check in visit for the next dosing period or the final visit.</description>
          <population>Any participants who received study product and had post dose assessments.</population>
          <units>Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.26"/>
                    <measurement group_id="O2" value="0.03" spread="0.25"/>
                    <measurement group_id="O3" value="0.03" spread="0.27"/>
                    <measurement group_id="O4" value="0.05" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.21"/>
                    <measurement group_id="O2" value="0.06" spread="0.22"/>
                    <measurement group_id="O3" value="0.09" spread="0.24"/>
                    <measurement group_id="O4" value="0.11" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.23"/>
                    <measurement group_id="O2" value="0.05" spread="0.27"/>
                    <measurement group_id="O3" value="0.09" spread="0.24"/>
                    <measurement group_id="O4" value="0.13" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.27"/>
                    <measurement group_id="O2" value="0.06" spread="0.27"/>
                    <measurement group_id="O3" value="0.04" spread="0.27"/>
                    <measurement group_id="O4" value="0.10" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.28"/>
                    <measurement group_id="O2" value="-0.02" spread="0.31"/>
                    <measurement group_id="O3" value="0.00" spread="0.28"/>
                    <measurement group_id="O4" value="0.05" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline for White Blood Cells With Differentials</title>
        <description>Change from baseline calculated by subtracting the Day -1 (baseline) hematology measurement from the 24 h post dose, and a follow up hematology measurement. Follow up is defined as either the check-in visit for the next period or the final visit. Hematology parameters included white blood cell count, and differential (absolute counts of neutrophils, lymphocytes, monocytes, eosinophils, and basophils).</description>
        <time_frame>Prior to dosing, 24 hour post dose through prior to the next dose (Day 8 or Final visit).</time_frame>
        <population>Any participants who received study product and had post dose laboratory assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for zoliflodacin administered orally on Day 1 of each dosing period
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.</description>
          </group>
          <group group_id="O4">
            <title>400 mg of Moxifloxacin</title>
            <description>400 mg of moxifloxacin administered orally on Day 1 of each dosing period
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline for White Blood Cells With Differentials</title>
          <description>Change from baseline calculated by subtracting the Day -1 (baseline) hematology measurement from the 24 h post dose, and a follow up hematology measurement. Follow up is defined as either the check-in visit for the next period or the final visit. Hematology parameters included white blood cell count, and differential (absolute counts of neutrophils, lymphocytes, monocytes, eosinophils, and basophils).</description>
          <population>Any participants who received study product and had post dose laboratory assessments.</population>
          <units>cells/microliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leukocytes: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-246.4" spread="1031.5"/>
                    <measurement group_id="O2" value="-129.9" spread="1249.6"/>
                    <measurement group_id="O3" value="-64.3" spread="1130.2"/>
                    <measurement group_id="O4" value="-282.9" spread="1075.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-273.5" spread="1253.1"/>
                    <measurement group_id="O2" value="140.3" spread="1486.1"/>
                    <measurement group_id="O3" value="35.8" spread="1153.9"/>
                    <measurement group_id="O4" value="-84.1" spread="1477.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-248.0" spread="667.7"/>
                    <measurement group_id="O2" value="-39.6" spread="955.3"/>
                    <measurement group_id="O3" value="-54.3" spread="1036.5"/>
                    <measurement group_id="O4" value="-351.3" spread="1008.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-272.2" spread="945.4"/>
                    <measurement group_id="O2" value="220.4" spread="1136.7"/>
                    <measurement group_id="O3" value="-36.1" spread="986.4"/>
                    <measurement group_id="O4" value="-59.2" spread="1216.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="583.2"/>
                    <measurement group_id="O2" value="-77.9" spread="499.6"/>
                    <measurement group_id="O3" value="-1.9" spread="549.7"/>
                    <measurement group_id="O4" value="79.4" spread="556.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.6" spread="497.9"/>
                    <measurement group_id="O2" value="-74.1" spread="530.5"/>
                    <measurement group_id="O3" value="96.9" spread="482.9"/>
                    <measurement group_id="O4" value="-33.7" spread="625.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="118.2"/>
                    <measurement group_id="O2" value="-13.9" spread="125.3"/>
                    <measurement group_id="O3" value="-10.6" spread="123.7"/>
                    <measurement group_id="O4" value="-16.1" spread="114.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="118.8"/>
                    <measurement group_id="O2" value="-7.6" spread="158.7"/>
                    <measurement group_id="O3" value="-25.4" spread="141.0"/>
                    <measurement group_id="O4" value="5.2" spread="138.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="65.1"/>
                    <measurement group_id="O2" value="4.0" spread="71.0"/>
                    <measurement group_id="O3" value="6.0" spread="72.8"/>
                    <measurement group_id="O4" value="8.2" spread="64.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="80.9"/>
                    <measurement group_id="O2" value="2.2" spread="83.9"/>
                    <measurement group_id="O3" value="0.7" spread="69.7"/>
                    <measurement group_id="O4" value="2.3" spread="61.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="13.8"/>
                    <measurement group_id="O2" value="-2.5" spread="13.3"/>
                    <measurement group_id="O3" value="-3.3" spread="13.5"/>
                    <measurement group_id="O4" value="-3.1" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="15.7"/>
                    <measurement group_id="O2" value="-0.5" spread="14.9"/>
                    <measurement group_id="O3" value="-0.2" spread="10.7"/>
                    <measurement group_id="O4" value="1.4" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline for Hemoglobin</title>
        <description>Change from baseline for hemoglobin is calculated by subtracting the Day -1 (baseline) hematology measurement from the 24 h post dose, and a follow up hematology measurement. Follow up is defined as either the check-in visit for the next period or the final visit.</description>
        <time_frame>Prior to dosing, 24 hour post dose through prior to the next dose (Day 8 or Final visit).</time_frame>
        <population>Any participants who received study product and had post dose laboratory assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for zoliflodacin administered orally on Day 1 of each dosing period
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.</description>
          </group>
          <group group_id="O4">
            <title>400 mg of Moxifloxacin</title>
            <description>400 mg of moxifloxacin administered orally on Day 1 of each dosing period
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline for Hemoglobin</title>
          <description>Change from baseline for hemoglobin is calculated by subtracting the Day -1 (baseline) hematology measurement from the 24 h post dose, and a follow up hematology measurement. Follow up is defined as either the check-in visit for the next period or the final visit.</description>
          <population>Any participants who received study product and had post dose laboratory assessments.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.71"/>
                    <measurement group_id="O2" value="0.01" spread="0.65"/>
                    <measurement group_id="O3" value="0.04" spread="0.67"/>
                    <measurement group_id="O4" value="-0.06" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.72"/>
                    <measurement group_id="O2" value="-0.23" spread="0.68"/>
                    <measurement group_id="O3" value="-0.06" spread="0.64"/>
                    <measurement group_id="O4" value="-0.13" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline for Hematocrit</title>
        <description>Change from baseline for hematocrit is calculated by subtracting the Day -1 (baseline) hematology measurement from the 24 h post dose, and a follow up hematology measurement. Follow up is defined as either the check-in visit for the next period or the final visit.</description>
        <time_frame>Prior to dosing, 24 hour post dose through prior to the next dose (Day 8 or Final visit).</time_frame>
        <population>Any participants who received study product and had post dose laboratory assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for zoliflodacin administered orally on Day 1 of each dosing period
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.</description>
          </group>
          <group group_id="O4">
            <title>400 mg of Moxifloxacin</title>
            <description>400 mg of moxifloxacin administered orally on Day 1 of each dosing period
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline for Hematocrit</title>
          <description>Change from baseline for hematocrit is calculated by subtracting the Day -1 (baseline) hematology measurement from the 24 h post dose, and a follow up hematology measurement. Follow up is defined as either the check-in visit for the next period or the final visit.</description>
          <population>Any participants who received study product and had post dose laboratory assessments.</population>
          <units>volume percentage of RBC in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="2.04"/>
                    <measurement group_id="O2" value="-0.10" spread="2.02"/>
                    <measurement group_id="O3" value="0.08" spread="2.08"/>
                    <measurement group_id="O4" value="-0.26" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="2.26"/>
                    <measurement group_id="O2" value="-0.69" spread="2.15"/>
                    <measurement group_id="O3" value="-0.10" spread="1.90"/>
                    <measurement group_id="O4" value="-0.33" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline for Erythrocytes</title>
        <description>Change from baseline for erythrocytes is calculated by subtracting the Day -1 (baseline) hematology measurement from the 24 h post dose, and a follow up hematology measurement. Follow up is defined as either the check-in visit for the next period or the final visit.</description>
        <time_frame>Prior to dosing, 24 hour post dose through prior to the next dose (Day 8 or Final visit).</time_frame>
        <population>Any participants who received study product and had post dose laboratory assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for zoliflodacin administered orally on Day 1 of each dosing period
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.</description>
          </group>
          <group group_id="O4">
            <title>400 mg of Moxifloxacin</title>
            <description>400 mg of moxifloxacin administered orally on Day 1 of each dosing period
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline for Erythrocytes</title>
          <description>Change from baseline for erythrocytes is calculated by subtracting the Day -1 (baseline) hematology measurement from the 24 h post dose, and a follow up hematology measurement. Follow up is defined as either the check-in visit for the next period or the final visit.</description>
          <population>Any participants who received study product and had post dose laboratory assessments.</population>
          <units>10^6 cells/microliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythrocytes: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.050" spread="0.243"/>
                    <measurement group_id="O2" value="-0.008" spread="0.228"/>
                    <measurement group_id="O3" value="-0.002" spread="0.233"/>
                    <measurement group_id="O4" value="-0.031" spread="0.253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocytes: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.005" spread="0.280"/>
                    <measurement group_id="O2" value="-0.088" spread="0.249"/>
                    <measurement group_id="O3" value="-0.029" spread="0.212"/>
                    <measurement group_id="O4" value="-0.053" spread="0.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline for Platelets</title>
        <description>Change from baseline for platelets is calculated by subtracting the Day -1 (baseline) hematology measurement from the 24 h post dose, and a follow up hematology measurement. Follow up is defined as either the check-in visit for the next period or the final visit.</description>
        <time_frame>Prior to dosing, 24 hour post dose through prior to the next dose (Day 8 or Final visit).</time_frame>
        <population>Any participants who received study product for that dosing period and had post dose laboratory assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for zoliflodacin administered orally on Day 1 of each dosing period
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.</description>
          </group>
          <group group_id="O4">
            <title>400 mg of Moxifloxacin</title>
            <description>400 mg of moxifloxacin administered orally on Day 1 of each dosing period
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline for Platelets</title>
          <description>Change from baseline for platelets is calculated by subtracting the Day -1 (baseline) hematology measurement from the 24 h post dose, and a follow up hematology measurement. Follow up is defined as either the check-in visit for the next period or the final visit.</description>
          <population>Any participants who received study product for that dosing period and had post dose laboratory assessments.</population>
          <units>10^3 platelets/microliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Platelets: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="25.8"/>
                    <measurement group_id="O2" value="-10.3" spread="26.9"/>
                    <measurement group_id="O3" value="-10.5" spread="24.4"/>
                    <measurement group_id="O4" value="-15.4" spread="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="27.8"/>
                    <measurement group_id="O2" value="2.9" spread="30.4"/>
                    <measurement group_id="O3" value="6.2" spread="30.3"/>
                    <measurement group_id="O4" value="-3.8" spread="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline for Sodium, Potassium, Chloride and Bicarbonate</title>
        <description>Change from baseline calculated by subtracting the Day -1 (baseline) chemistry measurement from the 24 h post dose, and a follow up chemistry measurement. Follow up is defined as either the check-in visit for the next period or the final visit. Chemistry parameters included sodium, potassium. chloride and bicarbonate.</description>
        <time_frame>Prior to dosing, 24 hour post dose through prior to the next dose (Day 8 or Final visit).</time_frame>
        <population>Any participants who received study product for that dosing period and had post dose laboratory assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for zoliflodacin administered orally on Day 1 of each dosing period
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.</description>
          </group>
          <group group_id="O4">
            <title>400 mg of Moxifloxacin</title>
            <description>400 mg of moxifloxacin administered orally on Day 1 of each dosing period
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline for Sodium, Potassium, Chloride and Bicarbonate</title>
          <description>Change from baseline calculated by subtracting the Day -1 (baseline) chemistry measurement from the 24 h post dose, and a follow up chemistry measurement. Follow up is defined as either the check-in visit for the next period or the final visit. Chemistry parameters included sodium, potassium. chloride and bicarbonate.</description>
          <population>Any participants who received study product for that dosing period and had post dose laboratory assessments.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sodium: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.9"/>
                    <measurement group_id="O2" value="-0.1" spread="1.9"/>
                    <measurement group_id="O3" value="0.6" spread="1.9"/>
                    <measurement group_id="O4" value="0.7" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="2.3"/>
                    <measurement group_id="O2" value="-0.3" spread="1.7"/>
                    <measurement group_id="O3" value="0.6" spread="1.8"/>
                    <measurement group_id="O4" value="0.2" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.41"/>
                    <measurement group_id="O2" value="0.25" spread="0.39"/>
                    <measurement group_id="O3" value="0.17" spread="0.41"/>
                    <measurement group_id="O4" value="0.11" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.33"/>
                    <measurement group_id="O2" value="-0.02" spread="0.45"/>
                    <measurement group_id="O3" value="0.01" spread="0.40"/>
                    <measurement group_id="O4" value="-0.01" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="2.0"/>
                    <measurement group_id="O2" value="1.0" spread="1.9"/>
                    <measurement group_id="O3" value="1.4" spread="2.0"/>
                    <measurement group_id="O4" value="1.4" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="2.1"/>
                    <measurement group_id="O2" value="-0.3" spread="2.3"/>
                    <measurement group_id="O3" value="0.5" spread="1.7"/>
                    <measurement group_id="O4" value="0.1" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="2.4"/>
                    <measurement group_id="O2" value="0.1" spread="1.8"/>
                    <measurement group_id="O3" value="0.6" spread="1.9"/>
                    <measurement group_id="O4" value="0.4" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="2.2"/>
                    <measurement group_id="O2" value="-0.3" spread="2.2"/>
                    <measurement group_id="O3" value="0.3" spread="2.1"/>
                    <measurement group_id="O4" value="-0.1" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline for Magnesium, Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Total Bilirubin, Direct Bilirubin</title>
        <description>Change from baseline calculated by subtracting the Day -1 (baseline) chemistry measurement from the 24 h post dose, and a follow up chemistry measurement. Follow up is defined as either the check-in visit for the next period or the final visit. Chemistry parameters included magnesium, glucose (fasting), BUN, creatinine, total bilirubin, direct bilirubin</description>
        <time_frame>Prior to dosing, 24 hour post dose through prior to the next dose (Day 8 or Final visit).</time_frame>
        <population>Any participants who received study product for that dosing period and had post dose laboratory assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for zoliflodacin administered orally on Day 1 of each dosing period
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.</description>
          </group>
          <group group_id="O4">
            <title>400 mg of Moxifloxacin</title>
            <description>400 mg of moxifloxacin administered orally on Day 1 of each dosing period
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline for Magnesium, Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Total Bilirubin, Direct Bilirubin</title>
          <description>Change from baseline calculated by subtracting the Day -1 (baseline) chemistry measurement from the 24 h post dose, and a follow up chemistry measurement. Follow up is defined as either the check-in visit for the next period or the final visit. Chemistry parameters included magnesium, glucose (fasting), BUN, creatinine, total bilirubin, direct bilirubin</description>
          <population>Any participants who received study product for that dosing period and had post dose laboratory assessments.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Magnesium: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.13"/>
                    <measurement group_id="O2" value="0.03" spread="0.13"/>
                    <measurement group_id="O3" value="0.02" spread="0.14"/>
                    <measurement group_id="O4" value="0.01" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.12"/>
                    <measurement group_id="O2" value="0.00" spread="0.13"/>
                    <measurement group_id="O3" value="0.02" spread="0.13"/>
                    <measurement group_id="O4" value="0.01" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (fasting): 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="7.8"/>
                    <measurement group_id="O2" value="6.4" spread="9.7"/>
                    <measurement group_id="O3" value="4.2" spread="8.3"/>
                    <measurement group_id="O4" value="3.2" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (fasting): Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="8.7"/>
                    <measurement group_id="O2" value="1.5" spread="9.8"/>
                    <measurement group_id="O3" value="-0.6" spread="8.9"/>
                    <measurement group_id="O4" value="1.0" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="3.2"/>
                    <measurement group_id="O2" value="1.6" spread="3.0"/>
                    <measurement group_id="O3" value="1.4" spread="2.9"/>
                    <measurement group_id="O4" value="2.5" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="3.3"/>
                    <measurement group_id="O2" value="0.0" spread="2.9"/>
                    <measurement group_id="O3" value="0.1" spread="3.0"/>
                    <measurement group_id="O4" value="-0.2" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.082" spread="0.082"/>
                    <measurement group_id="O2" value="0.086" spread="0.072"/>
                    <measurement group_id="O3" value="0.003" spread="0.059"/>
                    <measurement group_id="O4" value="0.059" spread="0.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.034" spread="0.102"/>
                    <measurement group_id="O2" value="-0.011" spread="0.089"/>
                    <measurement group_id="O3" value="0.006" spread="0.071"/>
                    <measurement group_id="O4" value="-0.007" spread="0.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.25"/>
                    <measurement group_id="O2" value="0.14" spread="0.23"/>
                    <measurement group_id="O3" value="-0.01" spread="0.24"/>
                    <measurement group_id="O4" value="-0.04" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.21"/>
                    <measurement group_id="O2" value="-0.04" spread="0.14"/>
                    <measurement group_id="O3" value="-0.01" spread="0.17"/>
                    <measurement group_id="O4" value="-0.02" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.07"/>
                    <measurement group_id="O2" value="0.02" spread="0.06"/>
                    <measurement group_id="O3" value="0.00" spread="0.06"/>
                    <measurement group_id="O4" value="-0.01" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.06"/>
                    <measurement group_id="O2" value="0.00" spread="0.05"/>
                    <measurement group_id="O3" value="0.01" spread="0.06"/>
                    <measurement group_id="O4" value="-0.01" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline for Total Protein and Albumin</title>
        <description>Change from baseline calculated by subtracting the Day -1 (baseline) chemistry measurement from the 24 h post dose, and a follow up chemistry measurement. Follow up is defined as either the check-in visit for the next period or the final visit. Chemistry parameters included total protein and albumin.</description>
        <time_frame>Prior to dosing, 24 hour post dose through prior to the next dose (Day 8 or Final visit).</time_frame>
        <population>Any participants who received study product for that dosing period and had post dose laboratory assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for zoliflodacin administered orally on Day 1 of each dosing period
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.</description>
          </group>
          <group group_id="O4">
            <title>400 mg of Moxifloxacin</title>
            <description>400 mg of moxifloxacin administered orally on Day 1 of each dosing period
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline for Total Protein and Albumin</title>
          <description>Change from baseline calculated by subtracting the Day -1 (baseline) chemistry measurement from the 24 h post dose, and a follow up chemistry measurement. Follow up is defined as either the check-in visit for the next period or the final visit. Chemistry parameters included total protein and albumin.</description>
          <population>Any participants who received study product for that dosing period and had post dose laboratory assessments.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Protein: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.45"/>
                    <measurement group_id="O2" value="-0.42" spread="0.39"/>
                    <measurement group_id="O3" value="-0.45" spread="0.43"/>
                    <measurement group_id="O4" value="-0.45" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.49"/>
                    <measurement group_id="O2" value="-0.06" spread="0.39"/>
                    <measurement group_id="O3" value="-0.01" spread="0.40"/>
                    <measurement group_id="O4" value="0.03" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.25"/>
                    <measurement group_id="O2" value="-0.30" spread="0.23"/>
                    <measurement group_id="O3" value="-0.30" spread="0.24"/>
                    <measurement group_id="O4" value="-0.32" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.28"/>
                    <measurement group_id="O2" value="-0.05" spread="0.22"/>
                    <measurement group_id="O3" value="0.01" spread="0.23"/>
                    <measurement group_id="O4" value="0.02" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline for Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase (AP)</title>
        <description>Change from baseline calculated by subtracting the Day -1 (baseline) chemistry measurement from the 24 h post dose, and a follow up chemistry measurement. Follow up is defined as either the check-in visit for the next period or the final visit. Chemistry parameters included AST, ALT and AP.</description>
        <time_frame>Prior to dosing, 24 hour post dose through prior to the next dose (Day 8 or Final visit).</time_frame>
        <population>Any participants who received study product for that dosing period and had post dose laboratory assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for zoliflodacin administered orally on Day 1 of each dosing period
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.</description>
          </group>
          <group group_id="O4">
            <title>400 mg of Moxifloxacin</title>
            <description>400 mg of moxifloxacin administered orally on Day 1 of each dosing period
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline for Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase (AP)</title>
          <description>Change from baseline calculated by subtracting the Day -1 (baseline) chemistry measurement from the 24 h post dose, and a follow up chemistry measurement. Follow up is defined as either the check-in visit for the next period or the final visit. Chemistry parameters included AST, ALT and AP.</description>
          <population>Any participants who received study product for that dosing period and had post dose laboratory assessments.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AST: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="3.0"/>
                    <measurement group_id="O2" value="-2.7" spread="5.6"/>
                    <measurement group_id="O3" value="-2.7" spread="3.5"/>
                    <measurement group_id="O4" value="-2.8" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="5.6"/>
                    <measurement group_id="O2" value="0.0" spread="4.0"/>
                    <measurement group_id="O3" value="-0.5" spread="3.3"/>
                    <measurement group_id="O4" value="0.6" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="4.1"/>
                    <measurement group_id="O2" value="-1.7" spread="2.7"/>
                    <measurement group_id="O3" value="-1.7" spread="4.0"/>
                    <measurement group_id="O4" value="-1.4" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="6.9"/>
                    <measurement group_id="O2" value="1.6" spread="7.5"/>
                    <measurement group_id="O3" value="-0.6" spread="4.2"/>
                    <measurement group_id="O4" value="0.8" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="6.3"/>
                    <measurement group_id="O2" value="-3.9" spread="4.6"/>
                    <measurement group_id="O3" value="-4.1" spread="4.9"/>
                    <measurement group_id="O4" value="-4.2" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="8.1"/>
                    <measurement group_id="O2" value="-0.4" spread="7.0"/>
                    <measurement group_id="O3" value="-0.7" spread="4.8"/>
                    <measurement group_id="O4" value="1.0" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline for Glomerular Filtration Rate (GFR) - Estimated</title>
        <description>Change from baseline calculated by subtracting the Day -1 (baseline) chemistry measurement from the 24 h post dose, and a follow up chemistry measurement. Follow up is defined as either the check-in visit for the next period or the final visit.</description>
        <time_frame>Prior to dosing, 24 hour post dose through prior to the next dose (Day 8 or Final visit).</time_frame>
        <population>Any participants who received study product and had post dose laboratory assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for zoliflodacin administered orally on Day 1 of each dosing period
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.</description>
          </group>
          <group group_id="O4">
            <title>400 mg of Moxifloxacin</title>
            <description>400 mg of moxifloxacin administered orally on Day 1 of each dosing period
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline for Glomerular Filtration Rate (GFR) - Estimated</title>
          <description>Change from baseline calculated by subtracting the Day -1 (baseline) chemistry measurement from the 24 h post dose, and a follow up chemistry measurement. Follow up is defined as either the check-in visit for the next period or the final visit.</description>
          <population>Any participants who received study product and had post dose laboratory assessments.</population>
          <units>mL/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GFR: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.4" spread="11.1"/>
                    <measurement group_id="O2" value="-9.5" spread="8.1"/>
                    <measurement group_id="O3" value="-0.1" spread="8.1"/>
                    <measurement group_id="O4" value="-6.2" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GFR: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="16.3"/>
                    <measurement group_id="O2" value="1.8" spread="11.0"/>
                    <measurement group_id="O3" value="-0.7" spread="8.5"/>
                    <measurement group_id="O4" value="1.5" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Urinalysis Adverse Events Following Administration of Study Product</title>
        <description>Urine for the clinical laboratory test was collected on Day -1, 24 hour post dose and the check in for the following dosing period. The results for glucose dipstick, protein dipstick and occult blood - dipstick were reported in categorical results. The possibilities were negative, trace, 1+, 2+, and 3+. If the dipsticks were 1+ or greater, microscopic evaluations were performed for erythrocytes, leukocytes and bacteria. For microscopic results to be deemed abnormal, the results must be reported 6 or greater per high power field.</description>
        <time_frame>From study product administration (Day 1) through prior to the next dose (Day 8 or Final visit).</time_frame>
        <population>Any participants who received study product and had post dose laboratory assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for zoliflodacin administered orally on Day 1 of each dosing period
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.</description>
          </group>
          <group group_id="O4">
            <title>400 mg of Moxifloxacin</title>
            <description>400 mg of moxifloxacin administered orally on Day 1 of each dosing period
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Urinalysis Adverse Events Following Administration of Study Product</title>
          <description>Urine for the clinical laboratory test was collected on Day -1, 24 hour post dose and the check in for the following dosing period. The results for glucose dipstick, protein dipstick and occult blood - dipstick were reported in categorical results. The possibilities were negative, trace, 1+, 2+, and 3+. If the dipsticks were 1+ or greater, microscopic evaluations were performed for erythrocytes, leukocytes and bacteria. For microscopic results to be deemed abnormal, the results must be reported 6 or greater per high power field.</description>
          <population>Any participants who received study product and had post dose laboratory assessments.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose dipstick: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose dipstick: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein dipstick: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein dipstick: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood dipstick: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood dipstick: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocytes microscopic: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocytes microscopic: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes microscopic: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes microscopic: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bacteria microscopic: 24 hour post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bacteria microscopic: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in ECG Measures: PR Interval, QRS Duration, QT Interval, QTcF Interval and RR Interval</title>
        <description>Change from baseline in ECG is calculated by subtracting the baseline (pre-dose) measurement from the post-dose measurement. Post-dose measurements were taken 1 h, 2 h, 4 h, 24 h after dosing and prior to the next dose (follow up). The following ECG Parameters were analyzed: PR Interval (Interval From Onset of P-wave to the Onset of the QRS Complex), QRS Duration (Time From the Start of the Q-wave to the End of the S-wave), QT Interval (Interval From Onset of the Q-wave to the End of the T-wave), QTcF Interval (QT Interval Corrected by Fridericia's Formula) and RR Interval (Interval From the Peak of the R Wave of a QRS Complex to the Peak of the R Wave of the Next QRS Complex).</description>
        <time_frame>Baseline, 1 h, 2 h, 4h, 24 h post-dose and follow up</time_frame>
        <population>Any participants who received study product and had post dose ECG assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for zoliflodacin administered orally on Day 1 of each dosing period
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.</description>
          </group>
          <group group_id="O4">
            <title>400 mg of Moxifloxacin</title>
            <description>400 mg of moxifloxacin administered orally on Day 1 of each dosing period
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in ECG Measures: PR Interval, QRS Duration, QT Interval, QTcF Interval and RR Interval</title>
          <description>Change from baseline in ECG is calculated by subtracting the baseline (pre-dose) measurement from the post-dose measurement. Post-dose measurements were taken 1 h, 2 h, 4 h, 24 h after dosing and prior to the next dose (follow up). The following ECG Parameters were analyzed: PR Interval (Interval From Onset of P-wave to the Onset of the QRS Complex), QRS Duration (Time From the Start of the Q-wave to the End of the S-wave), QT Interval (Interval From Onset of the Q-wave to the End of the T-wave), QTcF Interval (QT Interval Corrected by Fridericia's Formula) and RR Interval (Interval From the Peak of the R Wave of a QRS Complex to the Peak of the R Wave of the Next QRS Complex).</description>
          <population>Any participants who received study product and had post dose ECG assessments.</population>
          <units>milliseconds (msec)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR Interval: 1 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="8.9"/>
                    <measurement group_id="O2" value="0.0" spread="7.7"/>
                    <measurement group_id="O3" value="1.3" spread="8.5"/>
                    <measurement group_id="O4" value="1.3" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval: 2 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="8.3"/>
                    <measurement group_id="O2" value="-0.7" spread="7.8"/>
                    <measurement group_id="O3" value="0.6" spread="7.6"/>
                    <measurement group_id="O4" value="0.4" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval: 4 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="8.0"/>
                    <measurement group_id="O2" value="-1.4" spread="8.3"/>
                    <measurement group_id="O3" value="-0.4" spread="7.8"/>
                    <measurement group_id="O4" value="-0.9" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval: 24 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="7.8"/>
                    <measurement group_id="O2" value="0.7" spread="7.9"/>
                    <measurement group_id="O3" value="0.5" spread="8.2"/>
                    <measurement group_id="O4" value="2.8" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="8.8"/>
                    <measurement group_id="O2" value="-1.9" spread="9.8"/>
                    <measurement group_id="O3" value="-3.1" spread="9.9"/>
                    <measurement group_id="O4" value="-0.9" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Duration: 1 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="4.1"/>
                    <measurement group_id="O2" value="-0.6" spread="5.1"/>
                    <measurement group_id="O3" value="0.4" spread="5.1"/>
                    <measurement group_id="O4" value="-0.5" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Duration: 2 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="6.6"/>
                    <measurement group_id="O2" value="-1.4" spread="4.9"/>
                    <measurement group_id="O3" value="-0.7" spread="5.9"/>
                    <measurement group_id="O4" value="-1.5" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Duration: 4 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="3.9"/>
                    <measurement group_id="O2" value="-1.0" spread="5.2"/>
                    <measurement group_id="O3" value="-0.7" spread="5.1"/>
                    <measurement group_id="O4" value="-1.6" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Duration: 24 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="4.9"/>
                    <measurement group_id="O2" value="-1.1" spread="6.8"/>
                    <measurement group_id="O3" value="-0.9" spread="5.0"/>
                    <measurement group_id="O4" value="-1.1" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Duration: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="6.0"/>
                    <measurement group_id="O2" value="0.3" spread="6.9"/>
                    <measurement group_id="O3" value="-1.1" spread="5.3"/>
                    <measurement group_id="O4" value="-0.2" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval: 1 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="13.1"/>
                    <measurement group_id="O2" value="-6.2" spread="12.2"/>
                    <measurement group_id="O3" value="-2.5" spread="11.1"/>
                    <measurement group_id="O4" value="-1.4" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval: 2 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="14.6"/>
                    <measurement group_id="O2" value="-7.6" spread="15.6"/>
                    <measurement group_id="O3" value="-3.6" spread="13.3"/>
                    <measurement group_id="O4" value="2.3" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval: 4 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="13.8"/>
                    <measurement group_id="O2" value="-9.1" spread="18.3"/>
                    <measurement group_id="O3" value="-3.8" spread="14.3"/>
                    <measurement group_id="O4" value="2.0" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval: 24 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" spread="12.3"/>
                    <measurement group_id="O2" value="-7.6" spread="15.9"/>
                    <measurement group_id="O3" value="-9.9" spread="15.1"/>
                    <measurement group_id="O4" value="-3.7" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" spread="20.7"/>
                    <measurement group_id="O2" value="-6.6" spread="21.1"/>
                    <measurement group_id="O3" value="-8.3" spread="20.2"/>
                    <measurement group_id="O4" value="-10.0" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval: 1 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="10.8"/>
                    <measurement group_id="O2" value="0.6" spread="9.3"/>
                    <measurement group_id="O3" value="-0.4" spread="9.2"/>
                    <measurement group_id="O4" value="9.2" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval: 2 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="9.9"/>
                    <measurement group_id="O2" value="2.0" spread="10.2"/>
                    <measurement group_id="O3" value="-2.9" spread="9.5"/>
                    <measurement group_id="O4" value="10.6" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval: 4 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="10.8"/>
                    <measurement group_id="O2" value="-1.3" spread="12.2"/>
                    <measurement group_id="O3" value="-3.0" spread="9.9"/>
                    <measurement group_id="O4" value="8.5" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval: 24 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="8.5"/>
                    <measurement group_id="O2" value="1.9" spread="9.3"/>
                    <measurement group_id="O3" value="-3.5" spread="10.3"/>
                    <measurement group_id="O4" value="4.1" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="12.7"/>
                    <measurement group_id="O2" value="-0.2" spread="12.8"/>
                    <measurement group_id="O3" value="-3.8" spread="14.4"/>
                    <measurement group_id="O4" value="-1.4" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Interval: 1 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.9" spread="99.9"/>
                    <measurement group_id="O2" value="-48.4" spread="86.0"/>
                    <measurement group_id="O3" value="-14.1" spread="80.6"/>
                    <measurement group_id="O4" value="-74.5" spread="100.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Interval: 2 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.5" spread="99.7"/>
                    <measurement group_id="O2" value="-68.7" spread="82.0"/>
                    <measurement group_id="O3" value="-3.3" spread="94.0"/>
                    <measurement group_id="O4" value="-59.0" spread="107.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Interval: 4 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.8" spread="94.7"/>
                    <measurement group_id="O2" value="-54.3" spread="102.3"/>
                    <measurement group_id="O3" value="-4.8" spread="113.1"/>
                    <measurement group_id="O4" value="-46.6" spread="114.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Interval: 24 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.6" spread="83.5"/>
                    <measurement group_id="O2" value="-66.9" spread="91.3"/>
                    <measurement group_id="O3" value="-45.9" spread="106.1"/>
                    <measurement group_id="O4" value="-56.8" spread="87.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Interval: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.6" spread="112.7"/>
                    <measurement group_id="O2" value="-45.6" spread="108.6"/>
                    <measurement group_id="O3" value="-32.4" spread="125.5"/>
                    <measurement group_id="O4" value="-62.1" spread="103.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in ECG Measures: Ventricular Rate</title>
        <description>Change from baseline in ECG Ventricular Rate is calculated by subtracting the baseline (pre-dose) measurement from the post-dose measurement. Post-dose measurements were taken 1 h, 2 h, 4 h, 24 h after dosing and prior to the next dose (follow up).</description>
        <time_frame>Baseline, 1 h, 2 h, 4h, 24 h post-dose and follow up</time_frame>
        <population>Any participants who received study product and had post dose ECG assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>2 g of Zoliflodacin</title>
            <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O2">
            <title>4 g of Zoliflodacin</title>
            <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for zoliflodacin administered orally on Day 1 of each dosing period
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.</description>
          </group>
          <group group_id="O4">
            <title>400 mg of Moxifloxacin</title>
            <description>400 mg of moxifloxacin administered orally on Day 1 of each dosing period
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in ECG Measures: Ventricular Rate</title>
          <description>Change from baseline in ECG Ventricular Rate is calculated by subtracting the baseline (pre-dose) measurement from the post-dose measurement. Post-dose measurements were taken 1 h, 2 h, 4 h, 24 h after dosing and prior to the next dose (follow up).</description>
          <population>Any participants who received study product and had post dose ECG assessments.</population>
          <units>beats/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ventricular Rate: 1 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="6.6"/>
                    <measurement group_id="O2" value="3.3" spread="5.3"/>
                    <measurement group_id="O3" value="0.9" spread="5.1"/>
                    <measurement group_id="O4" value="4.7" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ventricular Rate: 2 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="6.8"/>
                    <measurement group_id="O2" value="4.6" spread="6.2"/>
                    <measurement group_id="O3" value="0.4" spread="6.5"/>
                    <measurement group_id="O4" value="3.6" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ventricular Rate: 4 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="6.6"/>
                    <measurement group_id="O2" value="4.1" spread="7.5"/>
                    <measurement group_id="O3" value="0.2" spread="7.3"/>
                    <measurement group_id="O4" value="2.8" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ventricular Rate: 24 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="5.8"/>
                    <measurement group_id="O2" value="4.6" spread="6.4"/>
                    <measurement group_id="O3" value="2.9" spread="8.0"/>
                    <measurement group_id="O4" value="3.5" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ventricular Rate: Follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="8.2"/>
                    <measurement group_id="O2" value="3.1" spread="7.3"/>
                    <measurement group_id="O3" value="1.8" spread="8.9"/>
                    <measurement group_id="O4" value="3.9" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Unsolicited adverse events and serious adverse events (SAEs) were collected from study product administration to Day 8 after treatment administration or final visit.</time_frame>
      <desc>Treatment emergent adverse events were defined as new events post-dose, or worsening of existing conditions post-dose. The adverse events were captured by changes in laboratory values, vital signs, ECGs and unsolicited adverse events immediately post dose to Day 8 post each treatment administration or early termination, whichever came first.</desc>
      <group_list>
        <group group_id="E1">
          <title>2 g of Zoliflodacin</title>
          <description>2 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
        </group>
        <group group_id="E2">
          <title>4 g of Zoliflodacin</title>
          <description>4 g of zoliflodacin administered orally on Day 1 of each dosing period
AZD0914: Spiropyrimidinetrione antibacterial drug, powder (zoliflodacin) was reconstituted in 60 mL of water and dosed orally following an overnight fast, after which approximately 60 mL of water was added to the cup and consumed by the subject.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo for zoliflodacin administered orally on Day 1 of each dosing period
Placebo: Composed of 4g of the same excipients found in zoliflodacin. Powder was reconstituted in 60 mL of water and dosed orally. After the cup containing 60 mL of placebo was taken, approximately 60 mL of water was consumed by the subject to chase the initial dose.</description>
        </group>
        <group group_id="E4">
          <title>400 mg of Moxifloxacin</title>
          <description>400 mg of moxifloxacin administered orally on Day 1 of each dosing period
Moxifloxacin: Broad-spectrum 8-methoxy fluoroquinolone. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride was administered orally with 120 mL of water.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (22.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BACTERIAL TEST POSITIVE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM QT PROLONGED</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>HEART RATE DECREASED</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="69"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="67"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="70"/>
                <counts group_id="E4" events="16" subjects_affected="11" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="67"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>George A. Saviolakis, MD, PhD, Medical Director</name_or_title>
      <organization>DynPort Vaccine Company LLC, a GDIT Company</organization>
      <phone>1-240-651-8116</phone>
      <email>George.Saviolakis@gdit.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

